Polynucleic acid sequences for use in the detection and differentiation of prokaryotic organisms

ABSTRACT

The invention relates to the use of the GTPase gene family as a target for nucleic acid based assays for the detection and differentiation of prokaryotic organisms. The invention relates to polynucleic acids derived from gene sequences encoding prokaryotic GTPase (=GTP-binding) proteins, as well as their use in the detection and identification of prokaryotic organisms; primers and probes derived from said polynucleic acid sequences, for specific amplification and detection of prokaryotic DNA in a biological sample; as well as methods and kits allowing the detection and identification of at least one micoroorganism, and preferentially several microorganisms simultaneously in a sample. More specifically, the invention relates to new polynucleic acid sequences encoding GTPase proteins from Campylobacter species, primers and probes derived from them, and methods and kits comprising these reagents for the detection and differentiation of species belonging to the genus Campylobacter.

The present invention relates to the use of the GTPase gene family as a target for nucleic acid based assays for the detection and differentiation of prokaryotic organisms.

The present invention relates to polynucleic acids derived from gene sequences encoding prokaryotic GTPase (=GTP-binding) proteins, as well as their use in the detection and identification of prokaryotic organisms; primers and probes derived from said polynucleic acid sequences, for specific amplification and detection of prokaryotic DNA in a biological sample; as well as methods and kits allowing the detection and identification of at least one micro-organism, and preferentially several micro-organisms simultaneously in a sample.

More specifically, the invention relates to new polynucleic acid sequences encoding GTPase proteins from Campylobacter species, primers and probes derived from them, and methods and kits comprising these reagents for the detection and differentiation of species belonging to the genus Campylobacter.

GTP-binding proteins (also called GTPases because of the GTP hydrolysis that they catalize) constitute a large family of proteins that all have a similar GTP-binding globular domain. When its bound GTP is hydrolysed to GDP, this domain undergoes a conformational change that inactivates the protein. It is well known that GTP-binding proteins in pro- and eukaryotic organisms show conserved structures and contain common amino acid sequence motifs at their GTP-binding sites (for a review see: Bourne et al., 1991). Although GTP-binding sites show a conserved motif at the amino acid level, sequences are only partially conserved at the nucleic acid level. Prokaryotic GTP-binding proteins have been amply described in literature, and often they are responsable for vital molecular functions in the cell, e.g. they function as elongation and initiation factors in protein synthesis (e.g. for E. coli; Zengel et al., 1984; March and Inouye, 1985; Laursen et al., 1981; Sacerdot et al., 1984) and they may have a role in protein translocation across membranes (e.g. for E. coli; Bernstein et al., 1989; Römisch et al., 1989; Gill et al. 1986). Some prokaryotic GTP-binding proteins have a still unknown function, like the era-protein from E. coli (Ahnn et al. 1986) or the spoOB-associated protein from Bacillus subtilis (Trach and Hoch, 1989).

It is an aim of the present invention to use the GTPase gene family as a target for nucleic acid based assays for the detection and differentiation of prokaryotic organisms.

It is an aim of the present invention to provide polynucleic acids derived from the GTPase gene family to be used for the detection and identification of one or several micro-organisms simultaneously in a sample. The use of the polynucleic acids of the invention can be embodied by the use as an oligonucleotide primer, capable of amplifying the prokaryotic polynucleic acids present in the sample, or by the use as an oligonucleotide probe, capable of hybridizing specifically to the polynucleic acids of the different micro-organisms present in the sample.

It is therefore an aim of the present invention to select primer sequences derived from the polynucleic acid sequences encoding prokaryotic GTPase proteins, said primer sequences allowing amplification of part of a GTPase gene of one micro-organism, or of several micro-organisms simultaneously.

It is a more specific aim of the present invention to select primer sequences from the polynucleic acid sequences encoding the GTP-binding sites, said primer sequences allowing the simultaneous amplification of part of a GTPase gene of several micro-organisms.

Another aim of the present invention is to select probe sequences from the polynucleic acid sequences encoding prokaryotic GTPase proteins, said probe sequences allowing specific detection and identification of one or several micro-organisms.

It is a more specific aim of the present invention to select probe sequences from the polynucleic acid sequences encoding the GTP-sites enclosed region, said probe sequences allowing the specific detection and differentiation of several micro-organisms.

It is also an aim of the present invention to provide a rapid and reliable method for the detection and identification of one or several micro-organisms simultaneously in a sample, using the above-mentioned polynucleic acids and/or oligonucleotides derived from them as principle reagents.

It is moreover an aim of the present invention to provide a kit enabling the detection and identification of one or several micro-organisms simultaneously in a sample, comprising the above-mentioned polynucleic acids and/or oligonucleotides derived from them as principle reagents.

In particular, it is an aim of the present invention to provide new polynucleic acid sequences encoding novel GTP-binding proteins, or part of them, from Campylobacter species.

It is more specifically an aim of the present invention to use said new GTPase genes as a target for the detection and differentiation of Campylobacter species.

It is in particular an aim of the present invention to provide for oligonucleotides, primers and probes, derived from said new polynucleic acid sequences, to be used in the specific detection and differentiation of Campylobacter species.

It is also a specific aim of the present invention to provide for a method and a kit enabling the detection and differentiation of Campylobacter species in a sample, and using the above-mentioned new polynucleic acids and/or oligonucleotides derived from them, as principle reagents.

All of these aims are achieved by the polynucleic acids of this invention.

The current invention makes use of the semi-conserved nature of the GTPase gene family, a property which proved to be advantageous for use in nucleic acid based assays applied to bacterial detection, differentiation and identification. Said nucleic acid based assays consist of amplification of the target sequences and/or hybridization to the target sequences. It is shown in the current invention that both universal as well as specific oligonucleotides can be derived from the polynucleic acid sequences encoding GTPases. Both kinds of oligonucleotides have their proper place in bacterial diagnosis, depending on the application.

The term “GTPase gene family” encompasses genes encoding GTPase (GTP binding) proteins (E.C.3.6.1.) in different prokaryotic organisms. These GTPase proteins are structurally related, especially at their GTP-binding sites which show conserved sequence motifs, but they may have different functions in vivo. Although GTPase proteins show a structural relatedness on the protein level, the relatedness on the DNA level may be much less clear.

The term “universal” oligonucleotide (probe and/or primer) signifies that this oligonucleotide hybridizes to and/or allows amplification of part of the GTPase genes from different taxa.

The term “specific” oligonucleotide (probe and/or primer) means that this oligonucleotide hybridizes to and/or allows amplification of part of the GTPase genes from only one taxon.

The term “taxon” may refer to a complete genus, or a subgroup within a genus, a species, or even a subtype within a species.

Depending on the application, the term “universal” oligonucleotide may thus refer to an oligonucleotide allowing the amplification of and/or the hybridization to part of the GTP-ase genes of most of the organisms of one genus, while, in that same application, the term “specific” oligonucleotide may refer to oligonucleotides allowing the amplification of and/or the hybridization to part of the the GTPase gene(s) of only one species of that genus (species-specific oligonucleotides).

The current invention shows that “universal” oligonucleotides may be derived from the polynucleic acid sequences encoding the GTP-binding sites of GTPase proteins, while “specific” oligonucleotides may be derived from the polynucleic acids sequences encoding the GTP-sites enclosed region. It is shown in the current invention that the polynucleic acid sequences encoding the “GTP-sites enclosed regions” are sufficiently variable between different species, and at the same time sufficiently conserved within one species, to allow the selection of species-specific probes from that region. This unique feature, combined with the rather conserved nature of the flanking regions encoding the GTP-binding sites, which allows the selection of universal primer sequences, make the GTPase gene family a particularly good target for nucleic acid based assays for the detection and differentiation of different prokaryotic organisms. This particular application of GTPase encoding nucleic acid sequences in the field of bacterial detection, identification and differentiation has not been suggested uptil now.

The abbreviation GTP stands for guanosine 5′-triphosphate.

The wording “GTP-binding sites” are those regions in the GTP-binding protein responsible for the binding of GTP. GTP-binding sites show evolutionary conserved amino acid motifs. According to Dever et al., 1987 most GTP-binding proteins show 3 to 4 conserved motifs, showing the following consensus sequences:

G-1: GXXXXGK

G-2: D(X)₁₀T

G-3: DXXG

G-4: NKXD

The expression “GTP-sites enclosed region” refers to the regions bracketed (flanked) by the GTP-binding sites. Since every GTPase usually contains several GTP-binding sites (see above), they also contain different GTP-sites enclosed regions (e.g. G1-G2, G2-G3, G3-G4, G1-G3 . . . ).

The Examples section describes the isolation and sequencing of new putative GTPase genes, or parts thereof, from Campylobacter species, said genes and the encoded proteins being called from now on c-gtp genes and c-gtp proteins. The examples section further shows the existence of corresponding gene sequences in other prokaryotic species. These corresponding gene and protein sequences, in species other than Campylobacter will be called from now on c-gtp-like genes and proteins.

The wording “c-gtp-like proteins and genes” thus refers to functionally and structurally related proteins to the c-gtp proteins, in prokaryotic organisms other than Campylobacter, and genes coding for the same. The c-gtp-like proteins are substantially homologous to the c-gtp proteins of Campylobacter, with a homology degree on the protein level in excess of 70%, preferably in excess of 80%, most preferably in excess of 90%. The homology on the DNA level may be much less, and preferably more than 50%. The c-gtp-like proteins and genes constitute the “c-gtp-family” of proteins and genes.

Examples I and II of the current invention describe the identification and sequencing of the full gene encoding a new putative GTP-binding protein of Campylobacter jejuni, called from now on the c-gtp-1 gene (and protein), the sequence of which is depicted in FIG. 2 (SEQ ID NO 1 and 2). Corresponding gene sequences are shown to exist in other Campylobacter species, as well as in other prokaryotic organisms (like Haemophilus influenzae and Mycobacterium leprae). Example III further demonstrates that oligonucleotide primers derived from the region encoding the GTP-binding sites in this protein allow the amplification of the target sequence in different thermophylic Campylobacter species, while oligonucleotide probes derived from the region encoding the GTP-sites enclosed region allow the differentiation between different thermophylic Campylobacter species. These experiments show that the c-gtp-1 gene family is a particular good target for the detection and differentiation of prokaryotic organisms, more particularly of Campylobacter species, and even more specifically of thermophylic Campylobacter species.

The wording “thermophylic Campylobacter species” comprises strains belonging to or being highly related to one of the following species: Campylobacter jejuni, C. coli, C. lari and C. upsaliensis. Thermophylic Campylobacter species are human pathogens commonly involved in infections causing diarrhea, usually as a result of digestion of contaminated food.

The wording “c-gtp-1 gene family” encompasses gene sequences encoding structurally and functionally related proteins to the c-gtp-1 protein of C. jejuni as depicted in FIG. 2 (SEQ ID NO 1), also called c-gtp-1 like genes and proteins. Examples of gene sequences from the c-gtp-1 family are depicted in FIG. 8 (SEQ ID NO 3-23) and may originate from organisms belonging to the genus Campylobacter or from other prokaryotic organisms.

Example V describes the identification and partial sequencing of another new putative GTPase gene isolated from Campylobacter species, from now on called c-gtp-2 gene (and protein). The sequence of part of this gene in different veterinary Campylobacter species is shown in the alignment of FIG. 16 (SEQ ID NO 83, 85 and 87). It is shown that analogues of this gene exist in other prokaryotic species (like Haemophilus influenzae, Eschericia coli and Acinetobacter). These analogue genes in species other than Campylobacter will from now on be called c-gtp-2 like genes (and proteins). It is further shown that oligonucleotides derived from the GTP-sites enclosed region of the c-gtp-2 like genes allow the detection and differentiation of different veterinary Campylobacter species. These experiments show that the c-gtp-2 gene family is a particular good target for the detection and differentiation of prokaryotic organisms, more particulary of Campylobacter species, and even more specifically of veterinary Campylobacter species.

The wording “veterinary Campylobacter species” encompasses species which are important in veterinary infections, like Campylobacter fetus, Campylobacter hyointestinalis and Campylobacter mucosalis.

The wording “c-gtp-2 gene family” encompasses gene sequences encoding structurally and functionally related proteins to the c-gtp-2 proteins of Campylobacter species, fragments of which are shown in FIG. 16 (SEQ ID NO 83, 85, 87, 89, 91, 93, 95). These related c-gtp-2 like genes and proteins may originate from organisms belonging to the genus Campylobacter or from other prokaryotic organisms.

Based on the fact that

the newly described GTPase genes and gene fragments have their homologous counterparts in organisms other than Campylobacter,

primers can be derived from these GTPase sequences allowing amplification of a corresponding gene fragment in different prokaryotic organisms,

probes can be derived from these GTPase gene sequences allowing differentiation between species belonging to the same genus (e.g. Campylobacter),

the current invention considers it fair to expect that this GTPase gene family is an ideal candidate target for the development of a quasi-universal prokaryotic detection and identification system, consisting of the simultaneous amplification of the GTPase gene, or at least a fragment thereof, from a number of different micro-organisms, followed by the specific detection of the different micro-organisms by hybridisation to specific probes, having this gene, or at least a fragment of it, as a target.

Since the advent of the polymerase chain reaction and some other nucleic acid amplification techniques, the impact of DNA-probe technology on the diagnosis of micro-organisms in samples of different origins is increasing. Being often more specific and potentially more sensitive—if an adequate amplification and/or detection system is used—the DNA probe approach may eventually replace the conventional identification techniques.

The reliability of polynucleic acid based tests essentially depends on the sensitivity and specificity of the probes and/or primers used. Thus the corner-stone of this type of assay is the identification of polynucleic acid sequences which are unique to the group of organisms of interest.

Most of the polynucleic acid based tests described in literature and/or commercially available aim at the detection of just one particular organism in a biological sample. Since certain samples may contain a variety of relevant micro-organisms, a multitude of separate assays would need to be performed to detect all relevant organisms possibly present. This is the case e.g. in biological samples, taken from human subjects suspected to be infected, or in food samples, originating from a contaminated food source, where a number of clinically relevant micro-organisms may be present. Performing a set of assays for each of the different pathogens separately would be expensive, laborious and time-consuming. Consequently, die number of tests actually performed in most routine diagnostic labs on a particular sample is restricted to just a few of the most relevant organisms. Therefore it would be extremely convenient to have access to a system which enables the fast, easy and simultaneous detection of a multitude of different organisms. The more organisms that can be screened for in the same assay, the more cost-effective the procedure would be.

The following definitions serve to illustrate the terms and expressions used in the different embodiments of the present invention as set out below:

The term “target” in the current invention means a polynucleic acid sequence which is amplified by the primers of the current invention and/or hybridized to the probes of the current invention. The target sequences aimed at in the current invention are the GTPase gene sequences or parts thereof.

The term “polynucleic acid” corresponds to either double-stranded or single-stranded cDNA or genomic DNA or RNA, containing at least 10, 20, 30, 40 or 50 contiguous nucleotides. Single stranded polynucleic acid sequences are always represented in the current invention from the 5′ end to the 3′ end.

Polynucleic acids according to the invention may be prepared by any method known in the art for preparing polynucleic acids (e.g. the phosphodiester method for synthesizing oligonucleotides as described by Agarwal et al. (1972), the phosphotriester method of Hsiung et al. (1979), or the automated diethylphosphoroamidite method of Baeucage et al. (1981)). Alternatively, the polynucleic acids of the invention may be isolated fragments of naturally occurring or cloned DNA or RNA.

The term “oligonucleotide” refers to a single stranded nucleic acid comprising two or more nucleotides, and less than 100 nucleotides. The exact size of an oligonucleotide depends on the ultimate function or use of said oligonucleotide. For use as a probe or primer the oligonucleotides are preferably about 5-50 nucleotides long.

The oligonucleotides according to the present invention can be formed by cloning of recombinant plasmids containing inserts including the corresponding nucleotide sequences, if need be by cleaving the latter out from the cloned plasmids upon using the adequate nucleases and recovering them, e.g. by fractionation according to molecular weight. The probes according to the present invention can also be synthesized chemically, e.g. by automatic synthesis on commercial instruments sold by a variety of manufacturers.

The nucleotides as used in the present invention may be ribonucleotides, deoxyribonucleotides and modified nucleotides such as inosine or nucleotides containing modified groups which do not essentially alter their hybridisation characteristics. Moreover, it is obvious to the man skilled in the art that any of the below-specified probes can be used as such, or in their complementary form, or in their RNA form (wherein T is replaced by U).

The oligonucleotides used as primers or probes may also comprise or consist of nucleotide analogues such as phosphorothioates (Matsukura et al., 1987). alkylphosphorothioiates (Miller et al., 1979) or peptide nucleic acids (Nielsen et al., 1991; Nielsen et al., 1993) or may contain intercalating agents (Asseline et al., 1984).

As most other variations or modifications introduced into the original DNA sequences of the invention, these variations will necessitate adaptions with respect to the conditions under which the oligonucleotide should be used to obtain the required specificity and sensitivity. However the eventual results of the hybridisation or amplification will be essentially the same as those obtained with the unmodified oligonucleotides.

The introduction of these modifications may be advantageous in order to positively influence characteristics such as hybridization kinetics, reversibility of the hybrid-formation, biological stability of the oligonucleotide molecules, etc.

The term “probe” refers to single stranded sequence-specific oligonucleotides which have a sequence which is sufficiently complementary to hybridize to the target sequence to be detected.

Preferably said probes are 70%, 80%, 90%, or more than 95% homologous to the exact complement of the target sequence to be detected. These target sequences are either genomic DNA or messenger RNA, or amplified versions thereof.

Preferably, these probes are about 5 to 50 nucleotides long, more preferably from about 10 to 30 nucleotides.

The term “hybridizes to” refers to preferably stringent hybridizations conditions, allowing hybridisation between sequences showing at least 70%, 80%, 90%, 95% or more homology with each other.

The term “primer” refers to a single stranded DNA oligonucleotide sequence capable of acting as a point of initiation for synthesis of a primer extension product which is complementary to the nucleic acid strand to be copied. The length and the sequence of the primer must be such that they allow to prime the synthesis of the extension products. Preferably the primer is about 5-50 nucleotides long. Specific length and sequence will depend on the complexity of the required DNA or RNA targets, as well as on the conditions of primer use such as temperature and ionic strength. The fact that amplification primers do not have to match exactly with the corresponding template sequence to warrant proper amplification is amply documented in the literature (Kwok et al., 1990).

The amplification method used can be either polymerase chain reaction (PCR; Saiki et al., 1988), ligase chain reaction (LCR: Landgren et al., 1988; Wu & Wallace, 1989; Barany, 1991), nucleic acid sequence-based amplification (NASBA; Guatelli et al., 1990; Compton, 1991), transcription-based amplification system (TAS; Kwoh et at., 1989), strand displacement amplification (SDA: Duck, 1990; Walker et al., 1992) or amplification by means of Qβ replicase (Lizardi et al., 1988; Lomeli et al., 1989) or any other suitable method to amplify nucleic acid molecules.

The term “labelled” refers to the use of labelled nucleic acids. This may include the use of labelled nucleotides incorporated during the polymerase step of the amplification such as illustrated by Saiki et al. (1988) or Bej et al. (1990) or labelled primers, or by any other method known to the person skilled in the art. Labels may be isotopic (³²P, ³⁵S, etc.) or non-isotopic (biotin, digoxigenin, etc.).

The term “complementary” nucleic acids as used in the current invention means that the nucleic acid sequences can form a perfect base paired double helix with each other.

The term “homologous” as used in the current application is synonymous for identical; this means that polynucleic acids (proteins) which are said to be e.g. 80% homologous show 80% identical base pairs (amino acids) in the same position upon alignment of the sequences.

The term “sample” refers to any biological material taken either directly from an infected human being (or animal), or after culturing (enrichment), or a sample taken from food or feed. Biological material may be e.g. faecal samples, urine, expectorations of any kind, broncheolavages, blood, skin tissue, biopsies, lymphocyte blood culture material, colonies, etc. Said samples may be prepared or extracted according to any of the techniques known in the art.

The term “solid support” can refer to any substrate to which an oligonucleotide probe can be coupled, provided that it retains its suitable hybridization characteristics and provided that the background level of hybridization remains low. Usually the solid substrate will be a microtiter plate, a membrane (e.g. nylon or nitrocellulose) or a microsphere (bead). Prior to application to the membrane or fixation it may be convenient to modify the nucleic acid probe in order to facilitate fixation or improve the hybridization efficiency. Such modifications may encompass homopolymer tailing, coupling with different reactive groups such as aliphatic groups, NH₂ groups, SH groups, carboxylic groups, or coupling with biotin, haptens or proteins.

As described above, the present invention thus relates to the use of the GTPase gene family as a target for nucleic acid based assays for the detection and/or differentiation of prokaryotic organisms.

The present invention more particularly relates to the use of the GTPase gene family as a target for nucleic acid based assays for the differentiation of prokaryotic organisms.

Nucleic acid based assays may include the amplification of the target nucleic acids and/or the hybridization of the (amplified) target nucleic acids, and the detection of the resulting amplification and/or hybridization products.

In particular, the current invention relates to the use of the GTPase gene family as a target for nucleic acid based assays for the detection and/or differentiation of different Campylobacter species.

More specifically, the current invention relates to the use of the c-gtp gene family as a target for nucleic acid based assays for the detection and/or differentiation of different Campylobacter species.

In a very specific embodiment the invention relates to the use of the c-gtp-1 family as a target for the detection and/or differentiation of thermophylic Campylobacter species.

The c-gtp-1 gene of Campylobacter jejuni is represented in FIG. 2 (SEQ ID NO 1). The different GTP-binding motifs in the corresponding c-gtp-1 protein are boxed. A characteristic feature of the c-gtp 1 protein is the repeat of the GTP-binding domain in the protein, which is clear from the structural organisation of the c-gtp-1 gene shown in FIG. 1. The presence of two GTP-binding domains in one protein is quite exceptional. After searching the protein data banks, only two other putative GTP-binding proteins were found to show an analogous repeat structure, i.e., a putative GTP-binding protein of Haemophilus influenzae (H10136) and a putative GTP-binding protein of Mycobacterium leprae (u0247e). An alignment of these three proteins, both on the structural level as on the sequence level is shown in FIGS. 12 and 11, respectively.

Part of the c-gtp-1 gene is also sequenced in other Campylobacter species, more specificalyy in the thermophylic Campylobacter species. C. coli, C. lari and C. upsaliensis. The sequences of the GTP-sites (G1-G3) enclosed region of the first GTP-binding domain in these different organisms, are represented in the alignment of FIG. 8 (SEQ ID NO 3-23).

All the above-mentioned c-gtp-1 like genes (and gene fragments) belong to the c-gtp-1 gene family.

Another embodiment of the invention relates to the use of the c-gtp-2 gene family as a target for nucleic acid based assays for the detection and/or differentiation of different Campylobacter species.

In a very specific embodiment the invention relates to the use of the c-gtp-2 gene family as a target for nucleic acid based assays for the detection and differentiation of different veterinary Campylobacter species.

The sequence of one of the GTP-sites (G1-G3) enclosed regions of the c-gtp-2 gene in different veterinary Campylobacter species is shown in FIG. 16 (SEQ ID NO 83, 85, 87). The corresponding fragments of the homologous genes from other prokaryotic organisms are aligned with it. These homologous sequences all belong to the c-gtp-2 gene family.

The present invention relates in particular to a polynucleic acid comprising one of the following sequences:

(i) the polynucleic acid sequence extending from nucleotide position 865 to position 2016 of SEQ ID NO 1, or

(ii) one of the polynucleic acid sequences represented by SEQ ID NO 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 16, 17, 18, 19, 20, 21, 22, or 23, or

(iii) one of the polynucleic acid sequences represented by SEQ ID NO 83, 85, 87, 89, 91, 93, or 95, or

(iv) a polynucleic acid sequence consisting of a fragment containing at least 8 contiguous nucleotides of any of the sequences as specified in (i) to (iii), or

(v) a polynucleic acid sequence complementary to any of the sequences as specified in (i) to (iv), or

(vi) a polynucleic acid sequence hybridizing to any of the sequences as specified in (i) to (v), or

(vii) a polynucleic acid sequence showing at least 50%, 60%, 70%, 80%, 90%, 95% or more homology to any of the sequences represented by (i) to (v), or

(viii) a polynucleic acid sequence as specified in any of (i) to (vii) wherein T is replaced by U, or other variants of the above specified sequences.

Other variants of the above-specified polynucleic acid sequences may contain modified nucleotides, such as inosine or nucleotides containing modified groups which do not alter essentially their hybridisation characteristics. They may also contain nucleotide analogues, such as phosphorothioates (Matsukura et al., 1987), alkylphosphorothioates (Miller et at., 1979) or peptide nucleic acids (Nielsen et al., 1991; Nielsen et al., 1993) or may contain intercalating agents (Asseline et al., 1984).

The “fragments” as defined in point (iv) of the above-mentioneded embodiment may be used in different applications. e.g. as a probe or as a primer, in different hybridization and/or amplification reactions.

More particularly, the present invention relates to the use of the above-mentioned polynucleic acid sequences for use in a diagnostic method. Even more particularly, the present invention relates to the preparation of a medicament for diagnosing at least one micro-organism, and preferably several micro-organisms simultaneously in a biological sample. The expression “the preparation of a medicament for diagnosing . . . ” refers to the preparation of a diagnostic composition.

The invention more particularly provides for said polynucleic acids to be used in the detection and identification of at least one micro-organism, and preferably several micro-organisms simultaneously in a biological sample.

The polynucleic acids of the invention as specified above encode c-gtp-1 proteins and the likes, or fragments thereof (SEQ ID NO 1, 3-23), or c-gtp-2 proteins and the likes, or fragments thereof (SEQ ID NO 83, 85, 87, 89, 91, 93 or 95) or the homologues of these proteins in other prokaryotic organisms.

It should be understood that the polynucleic acids of the invention are different from

the gene encoding a hypothetical protein H10136 of H. influenzae

the gene encoding a hypothetical protein u0247e of M. leprae

the gene encoding a hypothetical protein H10393 of H. influenzae

the gene encoding a hypothetical protein ECPTHGSH of E. coli.

These sequences encode c-gtp-1 and c-gtp-2 homologous proteins which have already been disclosed in the prior art, as described further in the Examples section.

It is clear that the polynucleic acids of the invention may also contain polynucleic acid sequences degenerate to any of the sequences SEQ ID NO 1, 3-23 and 83, 85, 87, 89, 91, 93, 95 as a result of the genetic code degeneracy, said degenerate sequences still encoding a prokaryotic c-gtp-like protein or part of it.

The polynucleic acids of the invention may also encode functional analogues of the above-mentioned proteins, said functional analogues being substantially homologous to the proteins encoded by any of the sequences represented by SEQ ID NO 1, 3 to 23, 83, 85, 87, 89, 91, 93 or 95.

By “substantially homologous” as used throughout the specification and the claims to describe proteins and peptides, is meant a degree of homology in the amino acid sequence to the proteins or peptides of the invention. Preferably the degree of homology is in excess of 80, preferably in excess of 90, with a particulary preferred group of proteins being in excess of 95 with the proteins and peptides of the invention.

From the above it is clear that the degree of homology within the family of polypeptides and the polynucleic acids of the invention is significantly higher on the protein level (70% or more) than on the DNA level (50% or more). It is therefor more appropiate to define the family of polynucleic acids of the invention by means of the polypeptides that they are encoding.

The term “functional analogue” refers to any protein or peptide having an amino acid sequence substantially identical to the sequence from which they are derived, whereby one or more amino acid residues have been conservatively substituted with a biologically equivalent residue. Examples of conservative substitutions include the substitution of one apolar (hydrophobic) residue such as isoleucine, valine leucine or methionine for another, the substitution of one polar (hydrophylic) residue for another such as between argininine and lysine, between glutamine and asparagine, between glycine and serine, the substitution of one basic residue such as lysine, arginine, or histidine, for another, or the substitution of one acidic residue, such as aspartic acid, or glutamic acid, for another. Examples of allowable mutations according to the present invention can be found in Table 1. Functional analogues may comprise isolates of the c-gtp genes in organisms other than Campylobacter, or may comprise muteins prepared in vitro from the above-specified sequences.

TABLE 1 Overview of the amino acid substitutions which could form the basis of functional analogues as defined above. Amino acids Synonymous groups Ser (S) Ser, Thr, Gly, Asn Arg (R) Arg, His, Lys, Glu, Gin Leu (L) Leu: Ile, Met, Phe, Val, Tyr Pro (P) Pro, Ala, Thr, GIy Thr (T) Thr, Pro, Ser, Ala, Gly, His, Gln Ala (A) Ala, Pro, Gly, Thr Val (V) Val, Met, lle, Tyr, Phe, Leu, Val Gly (C) Gly, Ala, Thr, Pro, Ser Ile (I) Ile, Met, Leu, Phe, Val, Tyr Phe (F) Phe, Met, Tyr, Ile, Leu, Trp, Val Tyr (Y) Tyr, Phe, Trp, Met, Ile, Val, Leu Cys (C) Cys, Ser, Thr, Met His (H) His, Gln, Arg, Lys, Glu, Thr Gln (Q) Gln, Glu, His, Lys, Asn, Thr, Arg Asn (N) Asn, Asp, Ser, Gln Lys (K) Lys, Arg, Glu, Gln, His Asp (D) Asp, Asn, Glu, Gln Glu (E) Glu, Gln, Asp, Lys, Asn, His, Arg Met (M) Met, Ile, Leu, Phe, Val

The present invention thus relates to a polynucleic acid comprising one of the following sequences, or fragments thereof:

(a) a polynucleic acid sequence encoding a c-gtp-like protein or fragment thereof, as defined above, or

(b) a polynucleic acid sequence encoding a functional analogue of the above-mentioned c-gtp-like protein, or

(c) a polynucleic acid sequence which is degenerate as a result of the genetic code degeneracy to the polynucleic acid sequences as defined in (a) or (b), or

(d) a polynucleic acid sequence hybridizing to any of the polynucleic acid sequences as defined in (a) to (c).

It should be understood that fragments of the above-mentioned polynucleic acids should contain a contiguous sequence of at least 8 nucleotides selected from the original polynucleic acid sequence.

It should be understood that the above-mentioned c-gtp-like genes and proteins originate from prokaryotic organisms.

In a more specific embodiment, the invention relates to polynucleic acids and the use thereof as described above, said polynucleic acids encoding c-gtp-like genes originating from Campylobacter species.

In a particular embodiment said polynucleic acids are used for detection and identification of one or several Campylobacter species simultaneously in a biological sample.

Another embodiment of the invention provides for an oligonucleotide primer derived from the GTPase gene family of sequences and hybridizing to the polynucleic acid sequences encoding the GTP-binding sites, said GTP-binding sites being represented by the following consensus sequences:

G-1: GXXXXGK^(S) _(T)

G-3: DXXG

G-4: NKXD.

Combination of two such primers, in a primerset, allows the amplification of the GTP-sites enclosed region.

The selection of the primer sequences should result preferentially in an oligonucleotide sequence capable of amplifying the GTP-sites enclosed regions of different taxa (e.g. different genera, different species, different subspecies) simultaneously.

A specific embodiment of the invention provides for an oligonucleotide primer selected from the c-gtp-gene family of sequences, and hybridizing to part of a polynucleic acid sequence as described above.

Preferably said primer comprises an oligonucleotide sequence containing from 5 to the maximum number of contiguous nucleotides, more preferably from 10 to 30 contiguous nucleotides of any of the sequences represented by SEQ ID NO 1, 3-23, 83, 85, 87, 89, 91, 93, 95 or their complementary sequences, or variants of said sequences, provided that said variants still allow the amplification of the c-gtp-like gene fragment of the taxon of interest.

The term “variants” of a primer includes variants differing in sequence by changing, adding or deleting one or more nucleotides, or by substituting one or more nucleotides withing said sequence, provided that said variants still allow amplification of the same nucleic acid fragments as the primers from which they are derived. The fact that amplification primers do not have to match perfectly with the corresponding template sequence to warrant proper amplification is amply documented in literature (e.g. Kwok et al. 1990).

Special note should be taken of the fact that the primers of the current invention can be used both as sense and as antisense primers. In the latter case, the sequence of the oligonucleotide primer should be the reverse complement of the sequences as specified in the current invention.

In a particular embodiment, the invention provides for a primer as described above, comprising or consisting of an oligonucleotide sequence which specifically hybridizes to the polynucleic acid fragments encoding the GTP-binding sites in the c-gtp-like genes as defined above, or their complementary sequences. This particular type of primer allows amplification of the GTP-sites enclosed regions of the c-gtp-like genes. Moreover, this type of primer may amplify the GTP-sites enclosed fragments of the gene in different prokaryotic micro-organisms, due to its conserved nature. Therefore, this type of primer will be preferentially used in a method for detection and identification of several micro-organisms simultaneously in a sample.

In a more specific embodiment of the invention a primer is provided as described above, comprising at least one of the following oligonucleotide sequences:

SEQ ID NO 24: CCAAATGTTGGAAAATCA

SEQ ID NO 25: GCCAAATGTTGGiAARTC

SEQ ID NO 26: AAiCCAAATGTTGGiAAR

SEQ ID NO 27: GGCAAiCCAAATGTiGG

SEQ ID NO 28: ATGTTGGAAAATCAAGYC

SEQ ID NO 29: ATCAAGTTTATTTAAC

SEQ ID NO 30: TAGACTTCGAAGAAAGCGC

SEQ ID NO 31: CATAGCAAGGCAAAGAATCGCC

SEQ ID NO 32: GATAGTGGAGGGCTTGAT

SEQ ID NO 33: GAYAGiGGAGGGCTTGAT

SEQ ID NO 34: GAYAGiSSAGGiCTiGAT

SEQ ID NO 35: GGGCTTGATGAAAGTGAT

SEQ ID NO 36: GGCTTTTTTTGAATGAATATGAAT

SEQ ID NO 37: CCCTCCACTATCAATAATAG

SEQ ID NO 38: GCCATCAATTTGTACTTCTA

SEQ ID NO 39: TTAAAAGCTCAGGCTTC

SEQ ID NO 80: AATAAAGTAGATAATAAAAAA

SEQ ID NO 81: AAYAARGTIGRiAAYAAAAAA

or variants of these primers, provided that said variants are still able to amplify part of the c-gtp-like gene(s) of the taxon of interest.

Primers represented by SEQ ID NO 24, 25, 26, 27 32, 33, 34, 35, 80 and 81 or variants thereof are derived from the GTP-sites and allow amplification of the GTP-sites enclosed region in one or several micro-organisms simultaneously.

Primers represented by SEQ ID NO 28, 29, 30, 31, 36, 37, 38, 39 or variants thereof are derived from the regions flanking the GTP-sites and allow species-specific amplification of part of the c-gtp genes.

In a specific embodiment, the invention provides for a set of primers as described above, able to amplify part of the c-gtp-like gene(s) in different prokaryotic organisms, and comprising at least one of the following sets of sequences:

A: SEQ ID NO 24 and SEQ ID NO 32

B: SEQ ID NO 25 and (SEQ ID NO 33 and SEQ ID NO 34)

C: SEQ ID NO 26 and (SEQ ID NO 33 and SEQ ID NO 34)

D: SEQ ID NO 27 and (SEQ ID NO 33 and SEQ ID NO 34)

E: SEQ ID NO 25 and SEQ ID NO 35

F: SEQ ID NO 26 and SEQ ID NO 35

and most preferably comprising the following set of primers:

B: SEQ ID NO 25 and (SEQ ID NO 33 and SEQ ID NO 34),

or variants of these primers, provided that said variants are still able to amplify part of the c-gtp-like gene(s) in different prokaryotic organisms.

In a more specific embodiment, the invention provides for a set of primers as described above, able to amplify the GTP-sites enclosed region of the c-gtp gene of Campylobacter species, and comprising at least one of the following sets of primers:

A: SEQ ID NO 24 and SEQ ID NO 32

B: SEQ ID NO 25 and (SEQ ID NO 33 and SEQ ID NO 34)

C: SEQ ID NO 26 and (SEQ ID NO 33 and SEQ ID NO 34)

and most preferably comprising the following set of primers:

C: SEQ ID NO 26 and (SEQ ID NO 33 and SEQ ID NO 34).

or variants of these primers, provided that said variants are still able to amplify the GTP-sites enclosed region of the c-gtp gene(s) in Campylobacter species.

In a more particular embodiment, the invention provides for a set of primers as described above, able to amplify part of the c-gtp-1 gene of Campylobacter jejuni, and comprising at least one of the following sets of primers:

SEQ ID NO 25 and (SEQ ID NO 33 and SEQ ID NO 34)

SEQ ID NO 26 and (SEQ ID NO 33 and SEQ ID NO 34)

SEQ ID NO 28 and SEQ ID NO 36,

or variants of these primers, provided that said variants are still able to amplify part of the c-gtp-1 gene in Campylobacter jejuni.

In a more particular embodiment, the invention provides for a set of primers as described above, able to amplify part of the c-gtp-1-like gene of Campylobacter coli, and comprising at least one of the following sets of primers:

SEQ ID NO 25 and (SEQ ID NO 33 and SEQ ID NO 34)

SEQ ID NO 26 and (SEQ ID NO 33 and SEQ ID NO 34)

SEQ ID NO 29 and SEQ ID NO 37,

or variants of these primers, provided that said variants are still able to amplify part of the c-gtp-1 like gene in Campylobacter coli.

In a more particular embodiment, the invention provides for a set of primers as described above, able to amplify part of the c-gtp-1 like gene of Campylobacter lari, and comprising at least one of the following sets of primers:

SEQ ID NO 25 and (SEQ ID NO 33 and SEQ ID NO 34)

SEQ ID NO 26 and (SEQ ID NO 33 and SEQ ID NO 34)

SEQ ID NO 30 and SEQ ID NO 38,

or variants of these primers, provided that said variants are still able to amplify part of the c-gtp-1 like gene in Campylobacter lari.

In a more particular embodiment, the invention provides for a set of primers as described above, able to amplify part of the c-gtp-1 like gene of Campylobacter upsaliensis, and comprising at least one of the following sets of primers:

SEQ ID NO 25 and (SEQ ID NO 33 and SEQ ID NO 34)

SEQ ID NO 26 and (SEQ ID NO 33 and SEQ ID NO 34)

SEQ ID NO 31 and SEQ ID NO 39.

or variants of these primers, provided that said variants are still able to amplify part of the c-gtp-1 like gene in Campylobacter upsaliensis.

In another embodiment, the invention provides for a set of primers as described above, able to amplify part of the c-gtp-2 gene of veterinary Campylobacter species, and comprising at least the following primer set:

SEQ ID NO 26 and (SEQ ID NO 33 and SEQ ID NO 34

or variants of these primers, provided that said variants are still able to amplify part of the c-gtp-2 like gene in veterinary Campylobacter species.

In another embodiment, the invention provides for a set of primers as described above, able to amplify part of the c-gtp-2 gene of Acinetobacter species, and comprising at least the following primer set:

SEQ ID NO 26 and (SEQ ID NO 33 and SEQ ID NO 34

or variants of these primers, provided that said variants are still able to amplify part of the c-gtp-2 like gene in Acinetobacter species.

The invention also provides for a combination of different primersets, said combination to be used simultaneously or consecutively in the amplification reaction. A combination of primersets can be used e.g. in a nested PCR reaction, aimed at a more sensitive and/or more specific detection.

Another embodiment of the invention provides for an oligonucleotide probe hybridizing with the GTPase gene family sequences, more specifically hybridizing with the GTP-sites enclosed region.

The selection of the probes according to the present invention occurs via a method as defined further, and results in probes allowing the identification of one taxon, and the differentiation towards other closely related taxa (=closest neighbours).

The term “closest neighbour” means the taxon which is known or expected to be most closely related in terms of DNA homology with the organism of interest and which has to be differentiated from it.

Another embodiment of the invention provides for an oligonucleotide probe hybridizing specifically with any of the above-defined polynucleic acids, said probe to be used for the specific detection of one or more micro-organisms by hybridisation to their polynucleic acids, either directly or after amplification of the polynucleic acids of the respective micro-organisms.

The invention further provides for an oligonucleotide probe as defined above selected from the c-gtp gene family of sequences and comprising part of any of the polynucleic acid sequences as defined above, or variants of said sequences, provided that said variants still hybridize specifically with the c-gtp-like gene fragment of the taxon of interest.

More particularly, the invention provides for a probe as described above, characterized by the fact that its sequence is contained in the region bracketed by the sequences coding for the GTP-binding sites of the c-gtp-like protein, this region being called the “GTP-sites enclosed region”. This region shows sufficient sequence diversity to allow differentiation of the species concerned from its closest neighbours and, on the other hand, sufficient sequence conservation to allow the detection of all strains of the species concerned.

The invention relates to an oligonucleotide probe as defined above obtainable by a process comprising the steps of:

(a) amplifying, using a pair of primers as described above, a GTP-sites enclosed region(s) present in the GTPase gene(s) of the organism to be determined, and repeating the same for a number of other organisms, phylogenetically closely related to the organism to be determined (=closest neighbours), or suspected of being present in the same type of sample as the organism to be determined,

(b) determining the sequences of the amplified regions,

(c) aligning the sequences obtained to allow mutual comparison, and selecting a region in the sequence of the organism to be determined, said region being characterized by a maximal sequence conservation within the organism to be determined, and a maximal sequence divergence (minimum 1 basepair mismatch) towards the other organisms,

(d) generating a probe comprising a sequence of at least 8 contiguous nucleotides from the region selected in (c),

(e) defining the hybridization conditions required to obtain the desired hybridization characteristics for the probe selected in (d).

It should be understood that probes obtained by the above-mentioned process may still need minor modifications to obtain the desired hybridization characteristics. Said modifications may include addition to and/or removal from any of their respective extremities of one or more nucleotides, or changing one or more nucleotides within said sequence.

The term “variants” of a probe refers to modified probe sequences as specified above. or probe sequences containing modified nucleotides, such as inosine or nucleotides containing modified groups which do not alter essentially their hybridisation characteristics. They may also contain nucleotide analogues, such as phosphorothioates (Matsukura et al., 1987), alkylphosphorothioates (Miller et al., 1979) or peptide nucleic acids (Nielsen et al., 1991; Nielsen et al., 1993) or may contain intercalating agents (Asseline et al., 1984).

In addition, it should be clear that all probes mentioned in the current invention can also be used in their complementary form.

The invention also relates to the above-mentioned method for the selection and generation of probes from the GTPase target gene family.

The expression “desired hybridisation characteristic” means that the probe only hybridizes to the DNA or RNA from organisms for which it was designed, and not to DNA or RNA from other organisms (closest neighbours or organisms liable to be present in the same sample). In practice, this means that the intensity of the hybridization signal is at least two, three, four, five, ten or more times stronger with the target DNA or RNA from the organisms for which the probes were designed, as compared to non-target sequences.

The hybridization conditions can be partially predicted from the oligonucleotide sequence of the probe according to principles known in the art. The conditions can be further monitored experimentally relying upon several parameters, such as the nature and concentration of the components of the media, and the temperatures under which the hybrids are formed and washed.

In a preferred hybridization medium, containing 5×SSC, hybridization temperatures can range from 35° to 65°, and more preferably from 40° to 50°. A preferred wash medium contains 2×SSC.

However, when modifications are introduced, be it either in the probes or the media, the temperatures at which the probes can be used to obtain the required specificity should be changed according to known relationships, such as those described in the following reference:

Hames B and Higgins S (eds.), Nucleic acid hybridization, A practical approach, IRL Press, Oxford, U.K., 1985.

Particularly, the invention provides for a probe as described above, hybridizing specifically to the DNA of thermophylic Campylobacter species, and comprising at least one of the sequences represented by SEQ ID NO 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, or 70, or any oligonucleotide probe selected from any of the sequences represented by SEQ ID NO 1, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 82 as long as said probe can be caused to hybridize specifically to DNA of thermophylic Campylobacter species, or variants of said probes, provided that said variants still hybridize specifically to the DNA of thermophylic Campylobacter species.

In a specific embodiment, the invention provides for an oligonucleotide probe as described above, hybridizing specifically to the DNA of Campylobacter jejuni, and comprising at least one of the sequences represented by SEQ ID NO 41, 42, 43, 44, 45, 61, 62, 63, 64, or any oligonucleotide probe selected from any of the sequences represented by SEQ ID NO 1, 3, 4, 5, 6, 7, 8, 9 or 10 as long as said probe can be caused to hybridize specifically to C. jejuni DNA, or variants of said probes, provided that said variants still hybridize specifically to the DNA of C. jejuni.

Another specific embodiment of the invention provides for an oligonucleotide probe as described above, hybridizing specifically to the DNA of C. coli and comprising at least one of the sequences represented by SEQ ID NO 46, 47, 48, 65, 66, 67, 68, or any oligonucleotide probe selected from any of the sequences represented by SEQ ID NO 11, 12, 13, 14, 15 or 16 as long as said probe can be caused to hybridize specifically to C. coli DNA, or variants of said probes, provided that said variants still hybridize specifically to the DNA of C. coli.

Another specific embodiment of the invention provides for an oligonucleotide probe as described above, hybridizing specifically to the DNA of C. lari and comprising at least one of the sequences represented by SEQ ID NO 49, 50, 51, 52, 53, 54, 55, 56, or any oligonucleotide probe selected from any of the sequences represented by SEQ ID NO 17, 18, 19, 20 or 21 as long as said probe can be caused to hybridize specifically to C. lari DNA, or variants of said probes, provided that said variants still hybridize specifically to the DNA of C. lari.

Another specific embodiment of the invention provides for an oligonucleotide probe as described above, hybridizing specifically to the DNA of C. upsaliensis and comprising at least one of the sequences represented by SEQ ID NO 57, 58, 59, 60, 69, 70, or any oligonucleotide probe selected from any of the sequences represented by SEQ ID NO 22 or 23 as long as said probe can be caused to hybridize specifically to C. upsaliensis DNA, or variants of said probes, provided that said variants still hybridize specifically to the DNA of C. uspsaliensis.

In another embodiment of the invention an oligonucleotide probe is provided as described above, hybridizing specifically to the DNA of veterinary Campylobacter species, and comprising at least one of the sequences represented by SEQ ID NO 71, 72, 73, 74, 75, 76, 77, 78, or 79, or any oligonucleotide probe selected from any of the sequences represented by SEQ ID NO 83 or 87, as long as said probe can be caused to hybridize specifically to DNA of veterinary Campylobacter species, or variants of said probes, provided that said variants still hybridize specifically to the DNA of veterinary Campylobacter species.

Another embodiment of the invention provides for an oligonucleotide probe as described above, hybridizing specifically to the DNA of Campylobacter fetus, and comprising at least one of the sequences represented by SEQ ID NO 71, 72, 73, 74, or 75, or any oligonucleotide probe selected from the sequence represented by SEQ ID NO 83 as long as said probe can be caused to hybridize specifically to DNA of Campylobacter fetus, or variants of said probes, provided that said variants still hybridize specifically to the DNA of Campylobacter fetus.

Another specific embodiment of the invention provides for an oligonucleotide probe as described above, hybridizing specifically to the DNA of Campylobacter hyointestinalis, and comprising an oligonucleotide sequence represented by at least one of the sequences represented in any of SEQ ID NO 76, 77, 78 or 79 or any oligonucleotide probe selected from the sequence represented by SEQ ID NO 87 as long as said probe can be caused to hybridize specifically to DNA of Campylobacter hyointestinalis, or variants of said probes, provided that said variants still hybridize specifically to the DNA of Campylobacter hyointestinalis.

Another embodiment of the invention provides for an oligonucleotide probe as described above, hybridizing specifically to the DNA of Acinetobacter species, and comprising part of any of the polynucleotide sequences represented by SEQ ID NO 89, 91, 93 or 95, as long as said probe can be caused to hybridize specifically to DNA of Acinetobacter species, or variants of said probes, provided that said variants still hybridize specifically to the DNA of Acinetobacter species.

Furthermore, the invention provides for a method for the detection and identification of at least one micro-organism, or the simultaneous detection of several micro-organisms in a biological sample, said method comprising the steps of:

(i) if need be releasing, isolating or concentrating the polynucleic acids present in the sample,

(ii) if need be amplifying part of the genomic DNA, with a set of primers as described above,

(iii) hybridizing the polynucleic acids of (i) or (ii) with at least one of the probes as described above,

(iv) detecting the hybrids formed in step (iii) with each of the probes under appropiate hybridization and wash conditions,

(v) identification of the micro-organisms present in the sample from the differential hybridisation signals obtained in (iv).

Detection and identification of the amplified products can be conveniently performed by using one of the many electrophoresis methods, hybridization methods or sequencing methods described in literature and currently known by men skilled in the art. However, a very convenient and advantageous technique for the simultaneous detection of nucleic acids possibly present in biological samples is the Line Probe Assay technique. The Line Probe Assay (LiPA) is a reverse hybridization format (Saiki et al., 1989) using membrane strips onto which several oligonucleotide probes (including negative or positive control oligonucleotides) can be conveniently applied as parallel lines.

The LiPA technique, as described by Stuyver et al. (1993) and in international Application WO 94/12670, provides a very rapid and user-friendly hybridization test. Results can be read within approximately 4 h, after the start of the amplification. After amplification during which usually a non-isotopic label is incorporated in the amplified product, and alkaline denaturation, the amplified product is contacted with the probes on the membrane and the hybridization is carried out for about 0.5 to 1.5 h. Consequently,, the hybrids formed are detected by an enzymatic procedure resulting in a visual purple-brown precipitate. The LiPA format is completely compatible with commercially availabe scanning devices, thus rendering automatic interpretation of the results very reliable. All those advantages make the LiPA format liable for use in a routine setting. The LiPA format therefore is particularly advantageous for detecting simultaneaously the presence of different pathogens possibly present in a sample.

The LiPA format is not only an advantageous tool for identification and detection of pathogens at the species level but also at higher or lower taxonomical levels. For instance, probe-configurations on LiPA strips can be selected in such a manner that they allow the detection of a complete genus (e.g. Campylobacter) or can identify species within a genus (e.g. C. jejuni, C. coli . . . ) or can in some cases even detect subtypes (subspecies, serovars, sequevars, biovars, etc. whatever is clinically relevant) within a species.

The fact that different probes can be combined on one strip also offers the possibility to conveniently cope with lack of sensitivity due to sequence heterogenity in the target region of the group of organisms to be detected. Due to this heterogenity, two or more probes may be required to positively detect all organisms of the particular group. These probes can be applied to membrane strips at different locations and the result is interpreted as positive if one of these probes is positive. Alternative these probes can be applied as a mixture at the same location, hereby reducing the number of lines on a strip. This reduction may be convenient in order to make the strip more concise or to be able to extend the total number of probes on one strip. An alternative advantage, in view of its practical benefits, is the synthesis of oligonucleotides harbouring the sequences of two (or more) different probes which can then be further processed and applied to the strip as one oligonucleotide molecule. This approach would considerably simplify the manufacturing procedures of the LiPA-strips. For example, probes with nucleotide sequences A and B are both required to detect all strains of taxon X. A probe can be synthesized having the nucleotide sequence AB. This probe will have the combined characteristics of probes A and B.

As an example, the procedure to be followed for the detection of a particular pathogen in a sample using the LiPA format is outlined below:

Firstly, the nucleic acid in the sample in which the infectious agent or agents present should be identified, is made available for amplification and/or hybridization.

Secondly, the nucleic acids are, if need be, amplified with one or another target amplification system. By using universal primers the GTP-sites enclosed region of most if not all organisms of eubacterial origin will be amplified.

The same result might be obtained by using a combination of different sets of primers with reduced universality. For some amplifications it might be convenient to amplify not all organisms present in the sample but more specifically, beforehand defined taxa. This might be achieved using either primers located in less conserved parts of the GTP-binding sites encoding regions or primers located in the GTP-sites enclosed region itself.

Usually, amplification is needed to enhance the subsequent hybridization signal. However for some samples or some organisms amplification might not be necessary. This might also be the case if, for the detection of the hybrids formed, highly sensitive signal-amplification systems are used.

Thirdly, after a denaturation step, the nucleic acids present in the sample or the resulting amplified product are contacted with LiPA strips onto which one or more DNA-probes are immobilized, allowing the detection of the organisms of interest, and hybridization is allowed to proceed.

Finally, after having performed a wash step, the hybrids are detected using a convenient and compatible detection system. From the hybridization signals or patterns observed the presence or absence of one or several organisms screened for in that particular biological sample can be deduced.

In a more particular embodiment, the invention provides for a method as described above, for detection of one or more thermophylic Campylobacter species, with said primer set comprising at least one set selected from the following sets of primers:

A: SEQ ID NO 24 and SEQ ID NO 32

B: SEQ ID NO 25 and (SEQ ID NO 33 and SEQ ID NO 34)

C: SEQ ID NO 26 and (SEQ ID NO 33 and SEQ ID NO 34)

and with said probes comprising least one of the sequences represented by SEQ ID NO 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, or 70, or any oligonucleotide probe selected from any of the sequences represented by SEQ ID NO 1, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 82 as long as said probe can be caused to hybridize specifically to DNA of thermophylic Campylobacter species, or variants of said probes, provided that said variants still hybridize specifically to the DNA of thermophylic Campylobacter species.

In a preferred embodiment, the invention provides for a method as described above, for detection of one or more thermophylic Campylobacter species, with said primer set comprising at least the following set of primers:

B: SEQ ID NO 25 and (SEQ ID NO 33 and SEQ ID NO 34)

and with said probes comprising at least one of the sequences represented by SEQ ID NO 40, 42, 50, 51, 62, 64, 66, 68, 69, or 70.

In another embodiment, the invention provides for a method as described above, for detection of one or more veterinary Campylobacter species, with said primer set comprising at least the following set of primers:

B: SEQ ID NO 25 and (SEQ ID NO 33 and SEQ ID NO 34)

and with said probes comprising at least one of the sequences represented by SEQ ID NO 71 to 79, or any probe derived from at least one of the sequences represented by SEQ ID NO 83 or 87.

The invention also provides for a method as described above, for detection and/oe differentiation of other species belonging to the genus Campylobacter, or belonging to other genera, in a biological sample, comprising at least one of the above-mentioned primers or probes.

In yet another particular embodiment the invention provides for a reverse hybridization method comprising any of the probes as described above, wherein said probes are immobilized on a known location on a solid support, more preferably on a membrane strip.

Other suitable assay methods for purposes of the present invention to detect hybrids formed between the oligonucleotide probes and the nucleic acid sequences in a sample may comprise any of the assay formats known in the art. For example, the detection can be accomplished using a conventional dot blot format, or by using sandwich hybridisation, competition hybridisation, strand displacement etc.

The invention also provides for a kit for detection and identification of at least one micro-organism, or the simultaneous detection and/or differentiation of several micro-organisms in a sample, comprising the following components:

(i) when appropiate, at least one suitable primer set as described above to allow amplification of part of the genomic DNA of said micro-organism(s),

(ii) at least one of the probes as described above,

(iii) a buffer, or components necessary to produce the buffer, enabling a hybridisation reaction between these probes and the nucleic acids present in the sample, or the amplified product.

(iv) a solution, or components necesary to produce the solution, enabling washing of the hybrids formed under the appropiate wash conditions,

(v) when appropiate, a means of detecting the hybrids resulting from the preceding hybridisation.

In a more particular embodiment, the invention provides for a kit as described above for detection and/or differentiation of thermophylic Campylobacter species in a sample, wherein said primerset comprises at least one set selected from the following sets of primers:

A: SEQ ID NO 24 and SEQ ID NO 32

B: SEQ ID NO 25 and (SEQ ID NO 33 and SEQ ID NO 34)

C: SEQ ID NO 26 and (SEQ ID NO 33 and SEQ ID NO 34)

and wherein said probes comprise at least one of the sequences represented by SEQ ID NO 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, or 70, or any oligonucleotide probe selected from any of the sequences represented by SEQ ID NO 1, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 82 as long as said probe can be caused to hybridize specifically to DNA of thermophylic Campylobacter species, or variants of said probes, provided that said variants still hybridize specifically to the DNA of thermophylic Campylobacter species.

In a more particular embodiment, the invention provides for a kit as described above for detection and/or differentiation of veterinary Campylobacter species in a sample, wherein said primerset comprises at least the following set of primers:

B: SEQ ID NO 25 and (SEQ ID NO 33 and SEQ ID NO 34)

and wherein said probes comprise at least one of the sequences represented by SEQ ID NO 71 to 79, or any oligonucleotide probe selected from any of the sequences represented by SEQ ID NO 83 or 87 as long as said probe can be caused to hybridize specifically to DNA of veterinary Campylobacter species, or variants of said probes, provided that said variants still hybridize specifically to the DNA of veterinary Campylobacter species.

FIGURE LEGEND

FIG. 1: Schematic representation of the organisation of the Campylobacter jejuni c-gtp-1 gene.

G1-G3-G4: regions corresponding to the GTP-binding sites, numbering according to Bourne et al., 1991.

Domain 1 and Domain 2: the 2 putative GTP-binding domains in the c-gtp-1 protein.

APS: autophosphorylation site

PRIBNOW: Pribnow consensus sequence

S&D: Shine and Delgarno consensus sequence

PCR fingerprint probe: 630 bp fragment isolated and described in Example 1

CR1: C. jejuni specific probe as described in example 1.

CR2, NCR1, NCR2: see Giesendorf et al. 1993

GTP-primerset: localization of the primersets used for amplification of a 160 bp fragment of the c-gtp-1 gene in thermophylic Campylobacter species as described in Example 1.

FIG. 2: c-gtp-1 gene of Campylobacter jejuni

Nucleic acid sequence of the full c-gtp-1 gene of C. jejuni (SEQ ID NO 1), and amino acid sequence of the corresponding protein (SEQ ID NO 2). Nucleic acid regions coding for the GTP-binding sites are boxed. The sequence corresponding to the 630 bp fragment of example 1 is delineated with arrows. GTP-binding domains 1 and 2 are also delineated. Pribnow and S&D sequences are underlined.

FIGS. 3-7: Amplification of the DNA of different thermophylic Campylobacter species using different primersets and different amplification conditions

lanes 1-33 and lanes 54-72: not relevant

lane 34: Campylobacter lari 70

lane 35: Campylobacter lari 79

lane 36: Campylobacter jejuni 87

lane 37: Campylobacter upsaliensis B542

lane 38: Campylobacter upsaliensis B572

lane 39: Campylobacter upsaliensis D391

lane 40: Campylobacter upsaliensis D432

lane 41: Campylobacter upsaliensis D457

lane 42: Campylobacter jejuni CW20

lane 43: Campylobacter jejuni CW31

lane 44: Campylobacter jejuni CW36

lane 45: Campylobacter jejuni CW38

lane 46: Campylobacter jejuni CW41

lane 47: Campylobacter jejuni (Inno nr 11284)

lane 48: Campylobacter coli 29

lane 49: Campylobacter coil 32

lane 50: Campylobacter coil 53

lane 51: Campylobacter coli 86

lane 52: Campylobacter coli 94

lane 53: Campylobacter coil (Inno nr 11283)

FIGS. 3A-3B: primerset A; annealing temperature: 50° C.

3a: agarose gel

3b: Southern blot of the gel in 3a using CR1 as a probe.

FIG. 4: primerset B; annealing temperature: 50° C., agarose gel

FIG. 5: primerset C; annealing temperature: 50° C., agarose gel

FIG. 6: primerset B; annealing temperature: 40° C., agarose gel

FIG. 7: primerset C; annealing temperature: 45° C., agarose gel

FIG. 8: Alignment of different GTP-sites enclosed regions from the c-gtp-1 gene family of different thermophylic Campylobacter species.

RINVSHORT: G1-G3 enclosed region from domain 1 of the c-gtp-1 gene of C. jejuni (SEQ ID NO 1, nucleot. pos 892to 1044)

SEQ ID NO 3-23: G1-G3 enclosed region from domain 1 of the c-gtp-1 gene of additional C. jejuni isolates (SEQ ID 3 to 10), of C. coli isolates (SEQ ID NO 11 to 16), of C. lari isolates (SEQ ID NO 17 to 21) and of C. upsaliensis isolates (SEQ ID NO 22 and 23), LIO numbers correspond to the ones in Table 2.

CJGTP2-13: =SEQ ID NO 82=G1-G3 enclosed region from domain 2 of the c-gtp-1 gene of C. jejuni (SEQ ID NO 1, nucleot. pos 1498 to 1608)

FIG. 9: Phylogenetic tree resulting from the alignment in FIG. 8.

cjgtp1_(—)13=910-1026 from RINVSHORT.

FIG. 10: Deduced amino acid sequence of the c-gtp-1 gene of C. jejuni. GTP-binding motifs from domain 1 and domain 2 are boxed. APS is underlined.

FIG. 11: Alignment of the deduced amino acid sequences from

(1) the c-gtp-1 gene of C. jejuni,

(2) a Haemophilus influenzae hypothetical protein HI0136 (Genbank access, No U32699)

(3) a Mycobacterium leprae hypothetical protein u0247e (Genbank access, No U00021).

“*” perfectly conserved residue

“.” well conserved residue

FIG. 12: Schematic representation of the alignment of FIG. 11.

FIG. 13: Alignment of GTP-based primers as used in primerset B, with G-1 and G-3 sites from domain 1 and 2 of the c-gtp-1 protein of C. jejuni. Sequences of the GTP 3.1 and is GTP 3.2 primers are noted in the antisense direction (=reverse complements from the sequences in Table 3).

FIG. 14: Outline of a LiPA for differentiation of thermophylic Campylobacter species.

FIG. 15: Experimental results obtained with a LiPA as outlined in FIG. 14.

lane J=hybridized to C. jejuni amplified DNA

lane C=hybridized to C. coli amplified DNA

lane L=hybridized to C. lari amplified DNA

lane U=hybridized to C. upsaliensis amplified DNA

lane B=negative control lane

FIG. 16: Alignment of c-gtp-2 gene fragments amplified with primerset B from different organisms:

“*”: character which is perfectly conserved

“.”: character which is well conserved

C.fetus 17_b= Campylobacter fetus LMG 6442

C.fetus _(—)16=Campylobacter fetus ATCC 33246

C.fetus18_B =Campylobacter fetus LMG 6569

Crect7_(—)13=Campylobacter rectus LMG 7614

Chyoi14_(—)13=Campylobacter hyointestinalis LMG 9276

Acin=Acinetobacter spp. various clinical isolates, classified according to Tjernberg and Ursing (1989) by DNA-DNA hybridization (DNA group between brackets): Acin2627 (13), Acin2284 (13), Acin468 (3), Acin1163 (3), Acin45 (8), Acin548 (8), Acin 549 (8).

HI0393=G1-G3 enclosed region from Haemophilus influenzae hypothetical protein HI0393, Genbank accession number L45034

ECPTHGSH=G1-G3 enclosed region from Escherichia coli K12 hypothetical GTP-binding protein ECPTHGSH Genbank accession number X61941. Corresponding protein sequence, accession number P31316{circumflex over ( )}Z

FIG. 17: Alignment of the deduced amino acid sequences from the nucleic acid sequences in FIG. 16.

FIG. 18: H. influenzae c-gtp-2 like protein (HI0393) sequence retrieved from Genbank (accession number L45034), G-1 and G-3 like sequences are indicated.

EXAMPLES Example I Isolation and Sequencing of a 630 bp Fragment of the c-gtp-1 Gene of Campylobacter jejuni

Introduction

Campylobacter jejuni is an important cause of diarrhea and, at present, more frequently isolated from stool specimens than Salmonella spp. and Shigella spp. together (Skirrow and Blaser, 1992). This necessitates fast and sensitive detection methods for this organism.

The conventional differentiation between all species of the genus Campylobacter is based on biochemical tests, antimicrobial resistance patterns and optimal growth temperatures. The identification of all these Campylobacters can be difficult because strains have relatively fastidious growth requirements, are asaccharolytic, and only a limited number of biochemical tests provide adequate discrimination. For instance, the hydrolysis of hippurate which is normally used to distinguish C. jejuni from C. coli, is not completely reliable (Roop et al., 1984).

To allow more cost-effective and specific detection and identification of Campylobacter species, methods other than the conventional biochemical tests, such as latex agglutination tests (LATs) and procedures based on DNA homologies have been developed. The more powerful methods, based on DNA homologies, can be applied for both taxonomical classification of Campylobacter species, culture confirmation and detection in clinical material (Goossens and Butzler, 1992; Wesley et al., 1991). In the 1980's. several groups have developed DNA probes, some of which are based on the 16S rRNA, for colony typing (Picken et al., 1987; Korolik et al., 1987; Ezaki et al., 1988; Romaniuk and Trust, 1989; Zhou and Wang, 1989). These probe-based methods also have the disadvantage that their sensitivity, estimated at 10⁵-10⁷ cfu/g faecal material, is relatively low and can lead to false-negative results for samples with a low infectious dose (Thorne et al., 1990; Taylor and Hiratsuka, 1990; Olive et al., 1990). Tenover et al. (1990) and Popovic-Uroic et al. (1991) evaluated the commercially available Accu Probe Assay System (Gen-probe Inc.) based on DNA probes labelled with acridinium esters, for confirmation of cultures from faecal samples. This system generated good results but unfortunately, the sensitivity of the assay was not estimated in these studies.

At present a few PCR assays for the detection of Campylobacter in food, environmental and clinical samples have been described. Oyofo et al. (1992) developed a PCR based on the 5′ end of the flaA gene of C. coli VC167. Wegmüller et al. (1993) designed a PCR assay based on the intergenic sequence between the flagellin genes flaA and flaB. Stonnet & Guesdon (1993) developed a PCR test specific for C. jejuni, based on a DNA fragment isolated from a C. jejuni CIP70.2 cosmid library. Van Camp et al. (1993) used the 16S rRNA gene and described a PCR assay that could not discriminate between the different thermophilic Campylobacter species. Eyers et al. (1993), however, developed a Campylobacter species-specific PCR assay based on the region located between helices 43 and 69 of the 23S rRNA.

The polymerase chain reaction (PCR) can also be used for genetic fingerprinting by random selection of primer annealing sites (Jayarao et al., 1992; Mc Millin and Muldrow, 1992; Walsh and Mc Clelland, 1991). These primer binding sites are distributed throughout the entire genome and amplification generates DNA fragments which differ in length. Numerous examples of this so-called PCR fingerprinting for determining relationships among strains and species of microorganisms have been published (for a review see Van Belkum, 1994).

For Campylobacter spp., PCR fingerprinting has been used in epidemiological studies of C. jejuni and C. upsaliensis (Giesendorf et al., 1994). Besides the generation of isolate-specific fragments, also species-specific fragments were selected that could be used as DNA probes on Southern blots containing genomic DNA from Campylobacter spp. and other microorganisms (Giesendorf et al., 1993). This species-specificity indicated the presence of unique sequences in the selected probe fragments.

One such fragment, selected for C. jejuni, was further characterised. The DNA fragment was cloned, the nucleic acid sequence was determined and similarity to known sequences was investigated. The fragment contained an open reading frame (ORF) coding for the N-terminal part (95 amino acids) of a protein. Screening of the Swiss protein library with the 95 amino acid sequence deduced from the ORF indicated similarity to the Escherichia coli Ras-like (Era) protein, a protein containing three GTP-binding sites (Ahnn et al., 1986). Similarity was highest at two possible GTP-binding sites present in the probe fragment. PCR primers, based on the GTP-binding sites, were used to investigate the conserved nature of these sites in other Campylobacter species. Furthermore, the nucleic acid sequence of the region flanked by the GTP binding sites (GTP-sites enclosed region) was determined in order to investigate the possibility to develop species-specific probes selected from this region.

Materials and Methods

Bacterial strains. Reference serotype strains of Campylobacter jejuni, C. coli and C. lari, used for DNA sequencing of the GTP-sites enclosed region, were obtained from H. Goossens (University Hospital Antwerp, Belgium), Strains were biotyped and serotyped according to Lior's scheme (Lior et al., 1982; Lior, 1984). A survey is presented in Table 2. Campylobacter upsaliensis strains used for sequencing were isolated from stool specimens of patients (St. Pieters Hospital, Brussels, Belgium).

A variety of other, non-reference Campylobacter strains were used for evaluating the PCR amplification reaction with different sets of primers (cfr. FIGS. 3-7). These strains were obtained from the Diagnostic Centre SSDZ, Delft, The Netherlands; the state Institute for Quality Control of Agricultural Products (RIKILT-DLO), Wageningen, The Netherlands; the National Institute of Public Health and Environmental Production (RIVM), Bilthoven. The Netherlands; the American Type Culture Collection (ATCC), Rockville Md. USA; the National Collection of Type Cultures (NCTC), London, England; the Culture Collection of the Laboratory for Microbiology, Ghent (LMG). Belgium; and the Slotervaart Hospital, Amsterdam, The Netherlands.

DNA isolation. DNA was isolated from pure cultures by standard procedures as described before (Giesendorf et al. 1993). After ethanol precipitation, the concentration of the DNA solution was estimated by electrophoresis on a 1% agarose gel in comparison with known amounts of lambda DNA as reference.

Isolation, cloning and sequence analysis of the C. jejuni specific fragment. The C. jejuni specific fragment was obtained after amplification of C. jejuni DNA with primers REP1R-1 and REP-2 as described before (Giesendorf et al., 1993). After electrophoresis the fragment was excised from the gel and purified by the Geneclean kit (Bio 101, La Jolla, Calif.). The purified 630 bp fragment was cloned into plasmid pGEM-T (Promega) which was transformed into Escherichia coli JM109. Sequence analysis was performed using the Pharmacia T7 sequencing system (Pharmacia, Uppsala, Sweden) using.|³⁵S|-dATP (Amersham). Gels were dried oil a Biorad vacuum gel dryer model 583 and exposed to Cronex 4 films (Dupont) at room temperature for 24-48 h. Sequence analysis was performed with the PCGene software (Intelligenetics, Mountain View, Calif., USA).

PCR. The PCR reaction mixtures (total volume of 100 μl) consisted of 10 mM Tris-HCl (pH 9.0), 50 mM KCl, 2.5 mM MgCl₂, 0.01% gelatin and 0.1% Triton X-100. Deoxyribonucleotide triphosphates were used at a final concentration of 0.2 mM. Per reaction, 0.25 U Super Taq DNA polymerase (Sphaero Q, Leiden, The Netherlands) was added.

Primers based on the GTP-binding sites. G-1 and G-3, and degenerated primers based on G-1 and G-3, were used (Table 3). Three different PCR programmes were used which involved 40 cycles of consecutive denaturation (1 min 94° C.), primer annealing (1 min 50° C. 45° C. or 40° C. for the three different programmes, respectively) and chain extension (1 min 74° C.). A Biomed thermocycler model 60 (Biomed. Germany) was used in all experiments. Primers were used at a concentration of 50 pmol per reaction. The following primersets were used: A. GTP3+GTP1, B. GTP1.1+(GTP3.1+GTP3.2); and C. GTP1.2+(GTP3.1+GTP3.2) (see Table 3).

Sequence analysis of the PCR fragments. After separation of PCR products, generated with primers GTP-3 and GTP-1, on a 2% low melting point agarose gel the DNA fragment of approximately 150 bp was excised from the gel and dissolved in 250 μl binding and washing buffer (B&W: 10 mM Tris-HCl (pH 7.5) 1 mM EDTA, 2 M NaCl) and 50 μl Dynabeads M-280 Streptavidin (Dynal) in B&W buffer (10 mg/ml) at 65° C. for 15 min. The beads were washed once with B&W buffer at 65° C. once with B&W buffer at room temperature and once with 10 mM Tris, 0.1 mM EDTA pH 7.5 (TE). Next, the beads were incubated with 50 μl 0.1 N NaOH, 10 min at room temperature, for denaturation of the DNA. The supernatant was transferred to a new tube and DNA was precipitated with 5 μl 3M NaCl, 1 μl polyA (20 mg/ml) and 100 μl 96% ethanol. After centrifugation for 10 min at 12000 g, the pellet was washed twice with 1 ml 70% ethanol, dried, suspended in 20 μl TE and stored at −20° C. for sequencing.

The beads were washed once with 50 μl 0.1 NaOH and twice with 100 μl TE. Finally the beads were suspended in 20 μl TE. Ten μl were used for sequence analysis using the Pharmacia T7 Sequencing Kit.

Results

Sequence determination of the 630 bp C. jejuni specific fragment. Three independent clones containing the C. jejuni specific 630 bp fragment were sequenced. No differences between the sequences obtained from these clones were found. The sequence of the 630 bp fragment is delineated with arrows in FIG. 2 (nucl. pos. 521 to 1149).

The following nucleotide sequence databases were screened for sequences homologous to the selected C. jejuni specific fragment: PDB (Brookhaven Protein Data Bank, April 1994)+GBUpdate (GenBank cumulative daily updates to EMBLUpdate+EMBL). GenBank vector (Vector subset of Genbank, April 1994)+repbase (Human and other primers Alu repeats, June 1994)+alu (select Alu repeats from REPBASE)+kabatnuc (Kabat Sequences of Nucleic Acid of Immunological Interest, August 1992)+epd (Eukaryotic Promotor Database Release 35, June 1993)+dbest (Database of Expressed Sequence Tag Release 2.29. August 1994)+dbst (Database of Sequenced Tags Sites Release 1.3. August 1994). No significant homologies were found.

Furthermore, the fragment sequence was screened for the presence of one or more ORFs. The start of an ORF was identified with an ATG initiation-codon (see position 865 on FIG. 2) and upstream of the ATG codon a sequence homologous to the 16S rRNA binding site consensus sequence (5′ AGGAAA 3′, position 856 on FIG. 2). Furthermore, a sequence homologous to the Pribnow consensus sequence also seems to be in a correct position (5′TATAAT 3′, position 845 on FIG. 2).

The following peptide sequence databases were screened for similarities to the 95 amino acid sequences deduced from the ORF, using the BLASTP 1.3.13MP (June 1994) software (4.59); PDB (Brookhaven Protein Data Bank, April 1994)+SwissProt (Release 29.0, June 1994)+PIR (Release 41.0, June 1994)+spupdate (SwissProt cumulative weekly update)+genpept (CDS translations from GenBank (R) Release 84.0, August 1994)+gpupdate (cumulative daily updates to the major release of genpept)+kabatpro (Kabat Sequences of Proteins of Immunological Interest Release 5.0, August 1992)+TFD (TFD transcription factor (protein) database Release 7.0, June 1993)+acr (Ancient Conserved Region subset of Swiss-Prot, December 1993)+alu (Translation of select Alu repeats from REPBASE). Some similarity was found with the Escherichia coli Ras-like (Era) protein, a protein containing three GTP binding sites (Ahnn et al., 1986). Similarity was highest at two putative GTP binding sites present in the fragment, located in the corresponding polynucleic acid sequence between positions 886-906 and 1027-1038 respectively (see FIG. 1 (G-1 and G-3) and FIG. 2). the rest of the protein showed no substantial homology.

Development of the GTP-PCR. Primers based on the GTP-binding sites G-1 and G-3 from the 630 bp fragment were selected: primers GTP-1 and GTP-3 (Table 3). Also degenerate primers, based on G-1 and G-3 were designed. Several primer combinations were evaluated on DNA from a selection of thermophylic Campylobacter strains at different annealing temperatures. The results are represented in FIGS. 3-7. The sequences of the primers and primer combinations are represented in Table 3.

Primersets B and C yielded a single PCR product of approximately 150 bp for each of the Campylobacter isolates at an annealing temperature of 50° C., whereas primerset A resulted in a more complex pattern with additional DNA fragments at the same annealing temperature. Lower annealing temperatures resulted in less specific amplification, or more complex patterns.

Sequence alignment of the GTP-sites enclosed region from the different Campylobacter species, and selection of species-specific probes. After amplification with primers GTP-1 and GTP-3, the nucleic acid sequence of the region enclosed by G-1 and G-3 from a selection of Campylobacter reference strains was determined as described in Material and Methods. FIG. 8 shows the sequence alignment of the region enclosed by G-1 and G-3 from several strains belonging to the following thermophylic Campylobacter species: C. jejuni, C. coli, C. lari and C. upsaliensis. A high degree of sequence variation between the different species is present whereas only few differences were found within a species. This enabled the design of a variety of species-specific probes from the GTP-sites enclosed region. for the different thermophylic Campylobacter species mentioned above, and also a probe specific for the group of thermophylic Campylobacter species. Among others, the following probe sequences can be used for the specific identification of the following Campylobacteria: general probe for thermophylic Campylobacteria:

SEQ ID NO 40: ACWAGAGATACMAATAAAA

specific probes for C. jejuni:

SEQ ID NO 41: CAGGTACAACTAGAGATACA (=CR1-probe described in Example 1)

SEQ ID NO 42: TTAATAGAATGGCAAGACAA

SEQ ID NO 61: TTTTTAATAGAATGGCAAGAC

SEQ ID NO 62: CTTTTTAATAGAATGGCAAGACAAAG

SEQ ID NO 43: TAGAATGGCAAGACAAAGAA

SEQ ID NO 44: ATATTTCAGGYACAACTAGA

SEQ ID NO 45: ATTCAAAAAAAGCCATGCTT

SEQ ID NO 63: CATTCAAAAAAAGCCATGCTT

SEQ ID NO 64: TTCATATTCATTCAAAAAAAGCCATGCTT

specific probes for C. coli:

SEQ ID NO 46: TCAAGTTTATTTAACAGAAT

SEQ ID NO 65: ATCAAGTTTATTTAACAGAATGG

SEQ ID NO 66: ATCAAGTTTATTTAACAGAATGGCAAG

SEQ ID NO 47: AAATTTCAGGTACTACAAGA

SEQ ID NO 48: TAAAACAGAAGTTTTTATAA

SEQ ID NO 67: CAATAAAACAGAAGTTTTTATAA

SEQ ID NO 68: CCAATAAAACAGAAGTTTTTATAAATTC

specific probes for C. lari:

SEQ ID NO 49: CTTTTTAATAGACTTGCAAG

SEQ ID NO 50: GACTTGCAAGAAAGCGCATA

SEQ ID NO 51: ACATAAGTGGAACCACAAGA

SEQ ID NO 52: TCACCAGTGACATAAGTGGA

SEQ ID NO 53: TGGAACCACAAGAGATACCA

SEQ ID NO 54: TGATGGCAAAAAAGCCTTGC

SEQ ID NO 55: GCATAGCTATCACCAGTGAC

SEQ ID NO 56: CAATAAAATAGAAGTACAAA

specific probes for C. upsaliensis:

SEQ ID NO 57: CGCATAGCAAGGCAAAGAAT

SEQ ID NO 69: TAATCGCATAGCAAGGCAA

SEQ ID NO 58: TTTCAGGCACGACTAGAGAT

SEQ ID NO 59: CAATGGTAAAGAAGCCTTGC

SEQ ID NO 70: TATCAATGGTAAAGAAGCCTT

SEQ ID NO 60: AAGAATCGCCATCACAAGTG

The probe sequences were selected such that there are a minimum of 2 mismatches with respect to the target sequences of other organisms. It is known to the man skilled in the art that, under appropiate hybridization and wash conditions, even 1 mismatch between probe and target sequence can be reliably detected. Hence all probes specified should be able to discriminate homologous target sequences from non-homologous target sequences. By way of an example, the results obtained with one these probes (SEQ ID NO 41) are discussed below. A further evaluation of these probes in a reverse hybridization assay can be found in Example IV.

Hybridization results with probe CR1. After PCR, using primerset A and annealing temperature 50° C., and agarose gel electrophoresis, the fragments were blotted onto a membrane and hybridized with probe CR1.

The hybridisation medium consisted of 5×SSC, 5×Dernhardt's solution, 5 mM EDTA, 0.5% SDS, 0.1 mg/ml herring sperm DNA. The specific activity of the labelled CR1-probe used was 10⁶ counts/ml. The hybridisation temperature was 42° C. and hybridisation was carried out overnight (16 u). Washing occurred also at 42° C. (15 min) in a medium consisting of 2×SSC and 0.1% SDS.

Species-specificity for the CR1-probe for C. jejuni (SEQ ID NO 41) is demonstrated in FIG. 3b, lanes 36 and 42-47. Those C. jejuni isolates showing a weaker hybridization contain a single mismatch to CR1 (see also alignment FIG. 8).

The above-demonstrated “thermophylic Campylobacter”—universal nature of the primers derived from the GTP-binding sites, combined with the species-specificity of the above-mentioned probes, allows the development of a rapid and reliable assay, consisting of the simultaneous amplification of DNA from different Campylobacter species, followed by the hybridization of the amplified fragment to a set of species-specific probes. This assay would be extremely useful for Campylobacter diagnostics in clinical, environmental and food samples.

TABLE 2 Campylobacter reference serotype strains used in this study Biotype Serovar Strain Source C. jejuni I LIO4 1/NCTC 11168 Human C. jejuni III LIO30 1215/A 1616 Human C. Jejuni III LIO61 5778/AP 39849 Human C. jejuni III LIO38 2418/Y 438 Human C. jejuni II LIO36 2074 Human C. jejuni I LIO39 3238/AP 14R81 Human C. jejuni II LIO49 3235/AP 11R81 Human C. jejuni II LIO23 720 Human C. jejuni I LIO28 1180 Human C. jejuni I LIO7 35 Human C. jejuni II LIO16 728 Human C. coli I LIO8 52 Human C. coli II LIO29 1982/SL 11 — C. coli II LIO78 8681/FR 119 Human C. coli I LIO21 699 Chicken C. coli II LIO24 1213/PC 349 Human C. coli I LIO80 8723/PERU PT 0412 Chicken C. coli I LIO47 3067/CA 72 — C. coli I LIO12 264 Human C. lari I LIO31 729 Human C. lari I LIO35 1728/MBS 25428 Sea gull C. lari I LIO73 8351/HAM 17735 Human C. lari I LIO64 5181/MBS 25453 Sea gull C. lari I LIO56 3331/BC 1135 Human

TABLE 3 Primers and primersets derived from the GTP-binding sites of the c-gtp-l gene of Campylobacter jejuni. All primer sequences are shown from 5′ to 3′ in the sense direction. It should be stressed however that these primers can be used both as sense or as anti- sense primers. In the latter case, the sequences as shown here should be converted to the reverse com- plement. G-1 site primers GTP1 CCAAATGTTGGAAAATCA SEQ ID NO 24 GTP1.1 GCCAAATGTTGGiAARTC SEQ ID NO 25 GTP1.2 AAiCCAAATGTTGGiAAR SEQ ID NO 26 GTP1.3 GGCAAiCCAAATGTiGG SEQ ID NO 27 G-3 site primers GTP3 GATAGTGGAGGGCTTGAT SEQ ID NO 32 GTP3.1 GAYAGiGGAGGGCTTGAT SEQ ID NO 33 GTP3.2 GAYAGiSSAGGiCTiGAT SEQ ID NO 34 GTP3.3 GGGCTTGATGAAAGTGAT SEQ TD NO 35 G-4 site primers GTP4 AATAAAGTAGATAATAAAAAA SEQ ID NO 80 GTP4.1 AAYAARGTIGRIAAYAAAAAA SEQ ID NO 81 Y = T or C R = G or A S = G or C i = inosine Possible primersets: A: GTP1 + GTP3 B: GTP1.1 + GTP3.1 + GTP3.2 C: GTP1.2 + GTP3.1 + GTP3.2 D: GTP1.3 + GTP3.1 + GTP3.2 E: GTP1.1 + GTP3.3 F: GTP1.2 + GTP3.3

Example II Isolation and Characterization of a Genomic DNA Fragment from Campylobacter jejuni Encoding the c-gtp-1 Protein

Isolation of Homologous Genomic Clones

In order to obtain the complete coding sequence of the c-gtp-1 protein, a putative GTP-binding protein of Campylobacter jejuni, part of which has been described in Example I, a genomic library of Campylobacter jejuni (described in Nuijten et al., 1990; kindly provided by prof. dr. B. A. M. van der Zeijst, University of Utrecht, the Netherlands), was screened with the 630 bp fragment described in Example I as a probe. This fragment was derived from Campylobacter jejuni genomic DNA by standard protocols (Sambrook et al., 1989). Screening of approximately 500,000 independent clones led to the isolation of several clones that showed strong hybridization to the 630 bp probe. Two clones were subjected to sequence analysis. A total sequence of 2047 bp was obtained (FIG. 2).

Characterization of the Genomic DNA Fragment

The 630 bp probe fragment is homologous to sequences between position 521 and 1149. Sequences showing homology to the REP1R-I (5′-iiiiCGUCGUCATCiGGC-3′) and REP-2 (5′-iCGiCTTATCiGGCCTAC-3′) primers, that were used to amplify the 630 bp fragment by PCR fingerprinting, are located between nucleotide positions 521-540 and 1139-1150, respectively.

The following datalibraries were screened for nucleotide sequences homologous to the 2047 bp sequence as shown in FIG. 2 by the Experimental GENINFO (R) BLAST Network Service (Blaster).

PDB (Brookhaven Protein Data Bank, April 1994 release)

Genbank (R) release 90, August 1995.

GBUpdate (GenBank cumulative daily updates)

EMBL Data Library release 43.0, June 1995.

EMBLU (EMBL Data Library cumulative daily updates)

GenBank vector (Vector subset of Genbank, February 1995)

alu (select Alu repeats from REPBASE)

kabatnuc (Kabat Sequences of Nucleic Acid of Immunological Interest) August 1995.

epd (Eukaryotic Promotor Database Release 40, September 1994)

dbest (Database of Expressed Sequence Tags, cumulative daily update)

dbsts (Database of Sequenced Tags Sites Release 1.5, October 1994).

No significant homologies were found.

The organisation of the genomic fragment is shown in FIG. 1. An open reading frame of 383 amino acids is located between nucleotide positions 865 and 2016, the amino acid sequence of this ORF is shown in FIG. 10.

The following datalibraries were screened for homologous amino acid sequences to this ORF using the Experimental GENINFO (R) BLAST Network Service (Blaster).

PDB (Brookhaven Protein Data Bank, April 1994 Release)

Swissprot (SWISS-PROT Release 31.0, March 1995)

PIR (PIR Release 45.0 (complete), Jun. 30, 1995)

Spupdate (SWISS-PROT cumulative weekly update)

Genpept (CDS translations from GenBank(R) Release 90, Aug. 15, 1995).

Gpupdate (cumulative daily updates).

Kabatpro (Kabat Sequences of Proteins of Immunological Interest, June 1995)

TFD (TFD transcription factor (protein) database Release 7.0, June 1993)

ALU (Translations of select Alu repeats from REPBASE)

Similarities were found to a number of proteins, as listed in table IV. The highest similarities were found for a Haemophilus influenzae hypothetical protein, a Mycobacterium leprae hypothetical protein, putative thiophene and furan oxidation proteins from Bacillus subtilis, Escherichia coli and Pseudomonas putida, and the Escherichia coli Ras-like (Era) protein (Ahnn et al., 1986). These proteins are all GTP-binding proteins.

GTP binding proteins are known to contain 3 to 4 GTP-binding regions each with a consensus sequence and with distinct spacings (Bourne et al., 1991; Dever et al., 1987). The deduced amino acid sequence from the Campylobacter jejuni c-gtp-1 gene also contains such regions.

The first GTP-binding motif (G-1, consensus sequence GXXXXGK^(S) _(T)) was found between amino acid positions 8 to 15 (See FIG. 2).

The second GTP-binding motif (G-2, consensus sequence D(X)₁₀T), was found at positions 31-42.

The third GTP-binding motif (G-3, consensus sequence DXXG) was found at positions 55-58.

The fourth motif (G-4, consensus NKXD) was found at positions 116-119.

Moreover, a putative autophosphorylation site (APS), similar to the E. coli era gene (ISGTTR), was found at positions 32-37.

Homologies between the deduced Campylobacter jejuni sequence, the Haemophilus influenza hypothetical protein (Genbank accession number U32699) and the Mycobacterium leprae hypothetical protein (Genbank accession number U00021) were further analyzed. Nucleotide sequences show no significant homologies. Also, overall sequence homologies among these proteins are very limited, except at the regions, designated as GTP-binding sites, as shown in the alignment of FIG. 11. The organizational alignment of the three amino acid sequences is shown in FIG. 12.

Remarkably, the conserved GTP-binding domains with the characteristic configuration of G-1 to G-4 motifs are present twice in the three proteins. Each of the proteins seems to contain two separate GTP binding domains.

As summarized in Table V, the spacing between domain 1 and domain 2 varies from 60 amino acids in Mycobacterium leprae to 98 amino acids in Haemophilus influenza. The spacing between the G-1 and G-3 motifs is 40 amino acids both in region 1 and region 2 in the three proteins. The spacing between the G-3 and G-4 motifs varies from 57 to 61 amino acids.

Since the 2 homologous protein sequences from M. leprae and H. influenzae show a clear structural relationship to the c-gtp-1 protein from C. jejuni, it is highly likely that they belong to the same family of c-gtp-1 gene sequences (c-gtp-1-like genes and proteins).

TABLE 4 Homologous sequences to the c-gtp-1 protein of Campylobacter jejuni. Accession Smallest sum number Description probability P(N) U32699 hypothetical protein H10136 9.3 E-46 Haemophilus influenzae U00021 hypothetical GTPbinding protein 7.6 E-39 u0247e Mycobacterium leprae P25811 Possible thiophene and furan 8.1 E-14 oxidation protein THDF - Bacillus subtilis P25755 Possible thiophene and furan 4.2 E-11 oxidation protein THDF - Pseudomonas putida P42182 Bex protein Bacillus subtilis 2.8 E-10 P32559 Yeast mitochondiral GTPase MSS1 3.2 E-10 precursor Z49211 Mss1p [Saccharomyces cerevisiae] 3.2 E-10 P25522 Thiophene and furane oxidation 5.4 E-10 protein THDF - Escherichia coli B36933 Era homolog - Streptococcus mutans 3.5 E-9 M67476 Theileria parva cathepsin L-like 4.2 E-9 cysteine protease and p67 genes U32781 Thiophene and furan oxidation 5.1 E-9 protein [Haemophilus influenzae] P37214 GTP-binding protein era homolog 8.1 E-8 U32687 GTP-binding protein [Haemophilus 1.4 E-6 influenzae] L27436 GTP-binding protein [Coxiella 2.9 E-5 burnetii] P06616 GTP-binding protein era 5.8 E-5 [Escherichia coli] P(N) = factor representing the probability that the homology found between the protein from table 4 and the c-gtp-1 protein of the invention is based on coincidence the smaller this number, the more significant is the homology found. E = Exponent 10

TABLE 5 Positioning of putative GTP-binding sites G-1 to G-4 in the amino acid sequences from Campylobacter jejuni (c-gtp-1 gene), Haemophilus influenzae HI0136 and Mycobacterium leprae u0247e. See also FIGS. 11 and 12. Domain Domain 2 G-1 G-3 G-4 G-1 G-3 G4 Campylobacter jejuni  8-14 55-58 116-119 202-208 249-252 313-316 Haemophilus influenza 10-16 57-60 120-123 222-228 269-272 334-337 Mycobacterium leprae 31-37 78-81 140-143 204-210 251-254 316-319

Comparison Between Domain 1 and Domain 2 Sequences

In order to determine the similarity between domain 1 and domain 2 GTP-binding sequences, a number of sequences were compared. The Campylobacter jejuni genomic fragment, domain 1 (CJGTP1_(—)13) and domain 2 (CJGTP2_(—)13) sequences were compared to sequences of fragments obtained from Campylobacter coli, Campylobacter lari and Campylobacter upsaliensis by amplification of genomic DNA with G-1 and G-3 based primers, as described in example I. The alignment of sequences and the resulting phylogenetic tree are shown respectively in FIGS. 8 and 9. The sequence from domain 2 is clearly distinct from the other sequences. This indicates that the GTP-sites enclosed region sequences, as described in example I are likely to be derived from domain 1.

To determine whether PCR primers GTP 1.1, GTP 3.1 and GTP 3.2 (primerset B, example I), based on G-1 and G-3 sites from domain 1 also allow amplification from G-1 and G-3 sites in domain 2, primer sequences were aligned with both regions. As shown in FIG. 13. G-1 sites from domain 1 and domain 2 are highly similar. Primer GTP 1.1 has only 3 mismatches at the extreme 5′ end with the G-1 site from domain 2. However, G-3 sequences from domain 1 and domain 2 are less similar. GTP 3.1 and GTP 3.2 primers have 7 mismatches with the G-3 site from domain 2. Conclusively, GTP 1.1 is likely to anneal efficiently at domain 2 sequences, whereas GTP 1.1 and GTP 3.2 are not likely to recognize G-3 from domain 2. Therefore, primerset B will only amplify domain 1 sequences, and the sequences represented in FIG. 8 (Example I) are corresponding to domain 1 sequences.

Example III Specificity Testing of GTP-site Based Primers

Introduction

Example I describes the development of PCR amplification of the GTP-sites enclosed region of the c-gtp-1 gene family in different Campylobacter species. Primers were selected from the semi-conserved nucleotide and amino acid sequences of two GTP-binding motifs, G-1 and G-3. These motifs are also present in GTP-binding proteins from various organisms.

The aim of the present example is to describe whether primers, selected from the sequence of GTP-binding sites encoding region in the c-gtp-1 gene of Campylobacter jejuni (as described in example I), also allow amplification of GTP-sites enclosed regions from other micro-organisms.

Previous experiments have shown that primerset B. consisting of sense primer GTP 1.1 and antisense primers GTP 3.1 and GTP 3.2, allows optimal amplification of 158 bp GTP-enclosed regions from Campylobacter jejuni, Campylobacter coli, Campylobacter lari, and Campylobacter upsaliensis. Therefore, the specificity and/or universality of this particular primerset B was further examined for a variety of micro-organisms belonging to the genus Campylobacter (Table 6) and to other prokaryotic genera (Table 8).

Materials and Methods

DNA Isolation

DNA was isolated from bacterial cultures by the following protocol.

1. Bacteria were harvested from plate by suspension in PBS.

2. To 500 μl of the suspension, proteinase K and SDS were added to final concentrations of 100 μg/ml and 0.5%, respectively.

3. The mixture was incubated at 37° C. until the suspension became clear.

4. The sample was extracted twice with phenol:chloroform:isoamylalcolhol (25:24:1).

5. The DNA is precipitated from the aqueous phase by addition of 1/10 volume 3M NaAc and 2 volumes of ethanol.

6. The DNA is resuspended in 100 μl water.

PCR Amplification

Amplification with primerset B was performed according to the following protocol.

1-10 μl DNA 10 μl 10x PCR buffer (final concentrations: 10 mM Tris-HCl (pH 9.0), 50 mM KCl, 2.5 mM MgCl₂, 0.01% gelatin and 0.1% Triton X-100). 20 μl dNTP's (final concentration 200 μM each) 50 pmoles sense primer GTP 1.1 25 pmoles antisense primer GTP 3.1 25 pmoles antisense primer GTP 3.2 1 μl Taq DNA polymerase (0.25 units: SpphaeroQ, Leiden, the Netherlands) . . . μl water 100 μl total volume

PCR Program

2 min. 95° C. preheating

40 cycles, consisting of 1 min. at 95° C., 2 min. at 50° C., 2 min. at 74° C.

5 min. 74° C., final extension.

Samples were analyzed on standard 2% agarose TBE gels.

Results

1. Specificity of Primerset B Among Campylobacter spp.

Amplification of genomic DNA isolated from the Campylobacter spp. listed in Table 6 yielded results as specified in Table 7.

All amplification products were also analyzed by reverse hybridization on a Line Probe Assay (LiPA) as described in example IV. The results of the LiPA are also provided in Table 7: they are confirming the species-specifity of the Campylobacter species probes on the LiPA strip. One species, C. hoyilei, shows an aberrant hybridization pattern, since it hybridizes with the probe for C. coli. However, there are several indications based on other taxonomic criteria (e.g. protein pattern analysis, genome homologies . . . ) that C. hoyilei is very closely related and possibly identical to C. coli.

2. Specificity of Primerset B Among Other Micro-organisms

DNA from all bacterial species, as listed in table 8, were subjected to PCR amplification with primerset B.

Results are summarized in table 8. The majority of the samples yielded no visible amplification products. Several bacterial species yielded DNA fragments of various sizes. To examine whether these fragments contain homologous sequences to the Campylobacter species-specific probes, all isolates that yielded any visible DNA fragment, were subjected to reverse hybridization as described in example IV. None of the tested non-Campylobacter bacterial species resulted in a detectable hybridization signal.

This confirms the specificity of the Campylobacter species-specific probes, present on the LiPA.

Conclusions

1. Primerset B results in amplification of a 158 bp fragment in C. jejuni, C. coli, C. lari, C. upsaliensis and C. hoyilei.

2. Primerset B results in amplification of a DNA fragment of ±200 bp in C. mucosalis.

3. Primerset B results in amplification of a DNA fragment of ±210 bp in C. fetus, C. rectum, C. hyointestinalis, Haemophilus influenzae and Acinetobacter spp.

4. Only amplified fragments from Campylobacter jejuni, C. coli, C. lari, and C. upsaliensis yield specific reverse hybridization patterns on LiPA. DNA fragments from C. fetus, C. rectum, C. hyointestinalis, C. mucosalis, as well as from non-Campylobacter bacteria did not result in any detectable reverse hybridization signal.

This example describes the use of primerset B for amplification of the G1-G3 enclosed region of GTPase-gene fragments in different prokaryotic organisms. Primerset B seems to be semi-conserved: some organisms show an amplified fragment (of varying size), other organisms show no detectable fragment after PCR. It should be stressed that, in an analogous way, other types of amplification could be carried out:

amplifications with a more or a less universal character:

By adapting the primer sequences (and possibly using degenerate primer sequences) amplifications can be made more specific (e.g. species or genus specific) or more universal. Less conserved primers can be chosen outside the GTP-binding site regions, resulting in more specific amplifications:

e.g. primersets for species specific amplification of

Campylobacter jejuni: SEQ ID NO 28 and SEQ ID NO 36

Campylobacter coli: SEQ ID NO 29 and SEQ ID NO 37

Campylobacter lari: SEQ ID NO 30 and SEQ ID NO 38

Campylobacter upsaliensis: SEQ ID NO 31 and SEQ ID NO 39

amplification of other GTP-sites enclosed regions (G1-G4, G3-G4):

by chosing the right primer combinations, other GTP-sites enclosed regions, can be amplified.

TABLE 6 Campylobacter spp. tested with primerset B Campylobacter jejuni LMG 6629 Campylobacter jejuni ATCC 33250 Campylobacter lari LMG 8846 Campylobacter coli LMG 6440 Campylobacter mucosalis LMG 8499 Campylobacter mucosalis LMG 8806 Campylobacter rectus LMG 7614 Campylobacter sputorum LMG 6447 Campylobacter sputorum ATCC 33491 Campylobacter concisus LMG 7789 Campylobacter concisus LMG 7963 Campylobacter concisus LMG 7967 Campylobacter hyointestinalis LMG 7538 Campylobacter hyointestinalis LMG 9276 Campylobacter showae LMG 8543 Campylobacter fetus ATCC 33246 Campylobacter fetus LMG 6442 Campylobacter fetus LMG 6569 Campylobacter fetus LMG 6727 Campylobacter fetus LMG 6571 Campylobacter curvus LMG 7609 Campylobacter hoyilei LMC 15882 Campylobacter upsaliensis clinical isolate (stool)

TABLE 7 Results of amplification of Campylobacter spp DNA with primerset B. reverse hybridization Campylobacter sp. size (bp) pattern (LiPA) C. jejuni 158 C. jejuni C. lari 158 C.lari C. coli 158 C.coli C. upsaliensis 158 C. upsaliensis C. mucosalis ±200   — C. rectus ±210   — C. sputorum none — C. concisus aspecific — C. hyointestinalis ±210   — C. showae none — C. fetus ±210   — C. curvus none — C. hoyilei 158 C.coli

TABLE 8 Non-Campylobacter bacterial species tested with primerset B - = no amplification product detectable on ethidium bromide stained agarose gel species source PCR result  1. Neisseria gonorrhoeae NCTC 8375 —  2. Neisseria meningitidis NCTC 10025 —  3. Neisseria lactamica NCTC 10616 —  4. Neisseria cinerea ATCC 14685 160 bp  5. Neisseria polysaccharea CIP N462 —  6. Neisseria elongata subsp. elongata NCTC 10660 —  7. Kingelia kingae NCTC 10746 —  8. Eikenella corrodens NCTC 10596 —  9. Neisseria spp. CDC group EF-4a CDC F191/78 — 10. Neisseria parelongata LMG 5354 —    (CDC group M-5) 11. Clostridium perfringens ATCC 12916 — 12. Listeria monoytogenes 4B NCTC 10527 300 bp 13. Streptococcus faecalis 8043 Hoechst — 14. Streptococcus agalactiae ATCC 13813 ±3 kb 15. Salmonella typhimurium ATCC 29946 faint smear 16. Staphylococcus aureus ATCC 6538p 300 bp 17. Shigella flexneri 2 RIVM 840947 faint smear 18. Staphylococcus epidermidis ATCC 12228 — 19. Proteus mirabilis ATCC 29906 faint smear 20. Kiebsiella pneumoniae ATCC 13883 faint smear 21. Salmonella enteritidis ATCC 13076 — 22. Acinetobacter species clin. isolates 210 bp 23. Pseudoinonas aeruginosa ATCC 27853 faint smear 24. Escherichia coli ATCC 11775 multiple 25. Enterobacter cloacae clin. isol. faint smear 26. Bacillus cereus myoides ATCC 11778 250 bp 27. Enterobacter agglomerans clin. isol. faint smear 28. Bacillus subtilis ATCC 6633 200 bp + ±4 kb 29. Enterococcus sp. clin. isoi. 350 bp 30. Enterococcus 378016 ″ — 31. Enterococcus 615156 ″ — 32. Enterococcus 320907 ″ — 33. Mycoplasma pneumoniae ″ — 34. Mycoplasma muris ″ — 35. Mycoplasma pulmonis ″ — 36. Mycoplasma iowae ″ — 37. Mycoplasma fermentans ″ — 38. Salmonella typhi 613240 ″ — 39. Salmonella typhi 615934 ″ — 40. Salmonella typhi clin. isol. — 41. Salmonella typhi clin. isol. — 42. Veillonella species clin. isol. — 43. Haemophilus influenzae ″ 210 bp 44. Bacteroides fragilis ″ ±4 kb 45. Clostridium freundii ″ — 46. Helicobacter pylori ATCC 43504 — 47. Proteus mirabilis clin. isol. — 48. Listeria monocytogenes 4b NTCT 10527 — 49. Klebsiella pneumoniae clin. isol. — 50. Enterobacter cloacae clin. isol. — 5i. Enterobacter agglomerans clin. isol. — 52. Clostridium perfringens ATCC 12916 — 53. Campylobacter laridis, stam 2 clin. isol. — 54. Shigeila flexneri clin. isol. — 55. Salmonella enteritidis clin. isol. —

Example IV Development of a Reverse Hybridization Assay for Campylobacter Species

Introduction

Example I describes the amplification of parts of the c-gtp-1 gene by PCR using various primersets. Primersets B and C resulted in the production of 158 bp fragments in C. jejuni, C. coli, C. lari, and C. upsaliensis. Primerset B has been used for further experiments. Sequence analysis of the PCR products obtained revealed consistent sequence conservation within each species as well as sequence diversity between different species. This observation led to the design of Campylobacter species-specific probes, that allow discrimination of at least the four species, mentioned above. This example describes the development of such probes for each of these four species. Furthermore, these probes were used in a reverse hybridization assay format, that allows identification of each PCR product by a single hybridization step.

Probe Design

Sequences, obtained from Campylobacter jejuni, C. coli, C. lari, and C. upsaliensis by PCR using primerset B, are shown in FIG. 8 of example I. Based on this sequence information, species-specific probes were synthesized, as listed in Table 9. Probes were designed such the probe sequences show a maximal conservation within a species, and a maximal divergence towards the sequence of the closest taxonomical neighbour from which the species should be differentiated. The probes, theoretically derived from the alignment, were then tested experimentally under different hybridization and wash conditions. Little modifications were necessary for some of the probes to obtain maximal sensitivity and specificity.

The probes performing optimally in a LiPA test at 50° C. hybridization temperature are marked with an asterisk in Table 9. It should be understood however that, depending on the experimental test conditions, other probe sequences, or variants of the ones shown in Table 9, may be equally functional.

LiPA-assay

An outline of the LiPA reverse hybridization format, containing the probes marked with an asterisk (*) is represented in FIG. 14. The LiPA was carried out according to the protocol described in International Application WO 94/12670. Primerset B was used for amplification, with the primers biotinylated at the 5′ end in order to allow detection of the hybrids formed. PCR reactions and programme were as described in example III. Hybridization was carried out at 50° C. Stringent wash at 50° C. in 2×SSC/0.1% SDS.

Results

Typical examples of developed LiPA strips are shown in FIG. 15. Results show that reactivity is as expected for the reference Campylobacter strains. These reactivities were also confirmed with a number of clinical isolates from the different Campylobacter species. Each probe line resulted in comparable signal intensities at 50° C.

Signal intensities are markedly reduced at 55° C. No aspecific reactivities were observed with other Campylobacter or non-Campylobacter strains.

TABLE 9 Species-specific probes tested in reverse hybridization LiPA SEQ ID NO Campylobacter sp. Probe sequence (5′to 3′) 45° C. 50° C. 42 C. jejuni TTAATAGAATGGCAAGACAA(*) C/L OK 61 C. jejuni TTTTTAATAGAATGGCAAGAC NT weak 62 C. jejuni CTTTTTAATAGAATGGCAAGACAAAG(*) NT OK 45 C. jejuni ATTCAAAAAAAGCCATGCTT L NT 63 C. jejuni CATTCAAAAAAAGCCATGCTT NT weak 64 C. jejuni TTCATATTCATTCAAAAAAAGCCATGCTT(*) NT OK 46 C. coli ATCAAGTTTATTTAACAGAAT OK neg 65 C. coli ATCAAGTTTATTTAACAGAATGG NT weak 66 C. coli ATCAAGTTTATTTAACAGAATGGCAAG(*) NT OK 48 C. coli AAAACAGAAGTTTTTATAA OK neg 67 C. coli CAATAAAACAGAAGTTTTTATAA NT weak 68 C. coli CCAATAAAACAGAAGTTTTTATAAATTC(*) NT OK 50 C. lari GACTTGCAAGAAAGCGCATA(*) OK OK 51 C. lari ACATAAGTGGAACCACAAG(*) OK OK 57 C. upsaliensis CGCATAGCAAGGCAAAGAA C NT 69 C. upsaliensis TAATCGCATAGCAAGGCAA(*) NT OK 59 C. upsaliensis CAATGGTAAAGAAGCCTTGC L NT 70 C. upsaliensis TATCAATGGTAAAGAAGCCTT(*) NT OK Abbreviations and symbols: C/L/U/J: means false positive reactions with resp. C. coli. C. lari. C. upsaliensis. C. jejuni neg: means no visable hydridization product weak: means only weakly detectable hybridization product NT: Not tested (*)probes selected as being the most optimal for a reverse hydridization test at 50° C. 45° C. and 50° C.: hybridization temperatures

Example V Isolation and Sequencing of Fragments of the c-gtp-2 Gene Family and Use of Said Gene Fragments for the Discrimination of Veterinary Campylobacter Species

Campylobacter spp. can be divided into at least two clinically important entities.

First, the thermophilic Campylobacter species, comprising C. jejuni, C. coli, C. lari, and C. upsaliensis, are important pathogens for humans. The use of GTP-based primers and specific probes for discrimination between the thermophilic species has been amply described in examples I to IV.

The second group comprises C. hyointestinalis, C. fetus and C. mucosalis, which are important in veterinary infections. This example describes the use of GTP primers to discriminate between these non-thermophilic Campylobacter species.

I. Amplification with GTP-based Primerset B

Amplification of C. rectus, C. hyointestinalis, C. fetus with primerset B did not yield a fragment of 158 bp as observed in thermophilic Campylobacter species, but resulted in production of a 210 bp fragment (see table 8). In addition, amplification of DNA from Acinetobacter spp. and Haemophilus influenzae with primerset B yielded a 210 bp fragment. Furthermore, C. mucosalis yielded a fragment of ±200 bp.

2. Sequence Analysis of PCR Products

In order to determine whether there was any significant degree of homology between the 210 bp fragments obtained from the different organisms (C. fetus, C. hyointestinalis, C. rectus, Haemophilus influenzae, and Acinetobacter), the amplicons were subjected to direct sequence analysis. Alignment of the nucleotide sequences is shown in FIG. 16. The alignment of the deduced amino acid sequences is shown in FIG. 17.

Both alignments indicate a significant degree of similarity between the sequences, and it is likely that they are derived from analogous genes, from now on called c-gtp-2 genes, clearly different from the c-gtp-1 gene family sequences described in examples I-IV. Since the genome of Haemophilus influenzae has been completely sequenced, the sequence from the 210 bp amplified fragment was compared with the sequence datalibrary by the GenInfo Blast server. The 210 bp fragment was completely homologous to the Haemophilus influenzae sequence deposited in Genbank with accession number L45034. This sequence encodes a hypothetical protein HI0393. the amino acid sequence of which is shown in FIG. 18.

In addition, a homologous c-gtp-2 like gene sequence from E. coli was retrieved from the Genbank datalibrary, under accession number X61941. This sequence encodes a hypothetical GTP-binding protein (ECPTHGSH). The sequence of the corresponding fragment of this E. coli gene (and protein) is shown in the respective alignments of FIGS. 16 and 17.

The amplification results mentioned above show that primers derived from the G-1 and G-3 sites from the c-gtp-1 gene from Campylobacter jejuni, and more particularly primerset B as described in example I, are sufficiently conserved to allow the amplification of other GTPase genes in other organisms. In particular, a fragment from another putative GTPase gene, c-gtp-2, is amplified in veterinary Campylobacter species, in Acinetobacter species, and in Haemophilus influenzae. Moreover, it is highly likely that a corresponding fragment would be amplified in other species, like e.g. in E. coli, where a c-gtp-2 homologous gene is shown to exist.

The following scheme shows an alignment of primerset B, containing primers GTP1.1, GTP3.1 and GTP3.2, with the G-1 and G-3 like sequences from the HI0393 protein (gene). G-1 and G-3-like sequences were found between amino acid positions 9 to 15 and 72 to 75, respectively. Although some mismatches occur, especially in the G-3 like sequences, amplification is still possible. The intervening sequence is 56 amino acids, and the total amplification product has a calculated size of 209 bp. No G-4 (NKVD)-like sequence could be detected.

G-1-like Sequence (Bold AA are Consensus)

aa9  G   L   P   N   V   G   K   S   T aa17 nt 24 GGA TTG CCA AAT GTC GGC AAA TCT ACT                   x GTP 1.1       G CCA AAT GTT GGI AAR TC

G-3-like Sequence

aa72  D   I   A   G   L   V  aa 77 GAC ATC GCA GGC TTA GTT nt 232      x   x    x x x  x GTP 3.1 GAY AGI GGA GGG CTT GAT      x          x    x GTP 3.2 GAY AGI SSA GGI CTI GAT

3. Selection of Species Specific Probes for Veterinary Campylobacter Species

From the alignment on FIG. 16 probe regions could be delineated for the specific determination of Campylobacter fetus and Campylobacter hyointestinalis, as specified below:

Specific probes for C. fetus: TTTTAATGCGTTAACAAAAC (SEQ ID NO 71) CTAGCAATGCAGAATCTGCA (SEQ ID NO 72) CTATCCATTTTGCACTATAG (SEQ ID NO 73) ATAGTTCCGGTTCCAGATAT (SEQ ID NO 74) TCCAGATATACGCTTAAATG (SEQ ID NO 75) Specific probes for C. hyointestinalis TTTTAATGCTCTAACAAAAC (SEQ ID NO 76) CTAGTAACGCAGAGGCNGCA (SEQ ID NO 77) CTATCNGTTTTGTACTATNG (SEQ ID NO 78) TNNTGATGCGCGTTTGAATG (SEQ ID NO 79)

REFERENCES

Agarwal et al. 1972. Agnew. Chem. Int. Ed. Engl. 11: 451.

Ahnn J., March P. E., Takiff H. E., and Isouye M. 1986. A GTP-binding protein of Escherichia coli has homology to yeast RAS proteins. Proc. Natl. Acad. Sci. USA 83:8849-8853.

Asseline U, Delarue M, Lancelot G, Toulme F, Thuong N (1984) Nucleic acid-binding molecules with high affinity and base sequence specificity: intercalating agents covalently linked to oligodeoxynucleotides. Proc. Natl. Acad. Sci. USA 81(11):3297-301.

Bej A, Mahbubani M, Miller R, Di Cesare J, Haff L, Atlas R (1990) Mutiplex PCR amplification and immobilized capture probes for detection of bacterial pathogens and indicators in water. Mol Cell Probes 4:353-365.

Baeucage et al. 1981. Tetrahedron Letters 22: 1859-1862.

Bernstein H et al. (1989) Nature 340, 482-486.

Boom R, Sol C, Salimans M, Jansen C, Wertheim van Dillen P and van der Noordas J (1990) Rapid and simple method for purification of nucleic acids. J Clin Microbiol 28:495-503.

Bourne H, Sanders D and McCormick F (1991) The GTPase superfamily: conserved structure and molecular mechanism. Nature, 349, 117-127.

Compton J (1991). Nucleic acid sequence-based amplification. Nature, 350:91-92.

Dever T E, Glynias M J, and Merrick W C, GTP-binding domain: Three consensus sequence elements with distinct spacing. Proc. Natl. Acad. Sci. USA. 1987, 84:1814-1818.

Duck P (1990). Probe amplifier system based on chimeric cycling oligonucleotides. Biotechniques 9, 142-147.

Eyers, M., S. Chapelle, G. Van Camp, H. Goossens, and R. De Wachter, 1993. Discrimination among thermophilic Campylobacter species by polymerase chain reaction amplification of 23S rRNA gene fragments. J. Clin. Microbiol. 31:3340-3343.

Ezaki, T., N. Takeuchi, S. L. Liu, A. Kai, H. Yamamoto, and E. Yabuuchi, 1988. Small-scale DNA preparation for rapid genetic identification of Campylobacter species without radioisotope. Microbiol. Immunol. 32:141-150.

Giesendorf B. A., Goossens H., Niesters H. G., Van Belkum A., Koeken A., Endtz H. P., Stegeman H., and Quint W. G., 1994. Polymerase chain reaction-mediated DNA fingerprinting for epidemiological studies on Campylobacter spp. J. Med. Microbiol. 40:141-147.

Giesendorf B. A., Quint W. G., Henkens M. H., Stegeman H., Huf F. A., and Niesters H. G. 1992. Rapid and sensitive detection of Campylobacter spp. in chicken products by using the polymerase chain reaction. Appl. Environ. Microbiol. 58:3804-3808.

Giesendorf B. A., Van Belkum A., Koeken A., Stegeman H., Henkens M. H., Van der Plas J., Goossens H., Niesters H. G., and Quint W. G. 1993. Development of species-specific DNA probes for Campylobacter jejuni, Campylobacter coli, and Campylobacter lari by polymerase chain reaction fingerprinting. J. Clin. Microbiol. 31:1541-1546.

Gill D. Hatfull G and Salmond G (1986) Molec. Gen. Genet. 205, 134-145.

Goossens, H. and J.-P. Butzler, 1992. Isolation and identification Campylobacter spp. p. 93-103. In I. Nachamkin, M. J. Blaser, and L. S. Tompkins (eds.). Campylobacter jejuni, current status and future trends. American Society for Microbiology, Washington DC.

Guatelli J, Whitfield K, Kwoh D, Barringer K, Richman D, Gengeras T (1990) Isothermal, in vitro amplification of nucleic acids by a multienzyme reaction modeled after retroviral replication. Proc Natl Acad Sci USA 87: 1874-1878.

Hsiung et al. 1979, Nucleic Acid Res. 6:1371.

Jayarao B. M., Bassem B. J., Caetano-Anoliès G., Gresshoff P. M., and Oliver S. P. 1992. Subtyping of Streptococcus uberis by DNA amplification fingerprinting. J. Clin. Microbiol. 30:1347-1350.

Korolik, V., P. J. Coloe, and V. Krishnapillai, 1988. A specific DNA probe for the identification of Campylobacter jejuni. J. Gen. Microbiol. 134:521-529.

Kwoh D, Davis G, Whitfield K, Chappelle H, Dimichele L, Gingeras T (1989). Transcription-based amplification system and detection of amplified human immunodeficiency virus type 1 with a bead-based sandwich hybridization format. Proc Natl Acad Sci USA, 86: 1173-1177.

Kwok S, Kellogg D, McKinney N, Spasic D, Goda L, Levenson C, Sinisky J, (1990). Effects of primer-template mismatches on the polymerase chain reaction: Human immunodeficiency views type 1 model studies. Nucl. Acids Res., 18: 999.

Landgren U, Kaiser R, Sanders J, Hood L (1988). A ligase-mediated gene detection technique. Science 241:1077-1080.

Laursen R, L'Italien J, Nakargatti S and Miller D (1981). J. Biol. Chem. 256, 8102-8109.

Lior H., Woodward D. L., Edgar J. A., Laroche L. J., and Gill P. 1982. Serotyping of Campylobacter jejuni by slide agglutination based on heat-labile antigenic factors. J. Clin. Microbiol. 15:761-768.

Lior H, 1984, New, extended biotyping scheme for Campylobacter jejuni, Campylobacter coli and “Campylobacter laridis”. J. Clin. Microbiol. 20:636-640.

Lizardi P, Guerra C, Lomeli H, Tussie-Luna I, Kramer F (1988) Exponential amplification of recombinant RNA hybridization probes. Bio/Technology 6:1197-1202.

Lomeli H, Tyagi S, Printchard C, Lisardi P, Kramer F (1989) Quantitative assays based on the use of replicatable hybridization probes. Clin Chem 35: 1826-1831.

March P and Inouye M (1985). J. Biol. Chem. 260, 7206-7213.

Matsukura M, Shinozuka K, Zon G, Mitsuya H, Reitz M, Cohen J, Broder S (1987) Phosphorothioate analogs of oligodeoxynucleotides: inhibitors of replication and cytopathic effects of human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 84(21):7706-10.

McMillin D. E., and Muldrow L. L. 1992. Typing of toxic strains of Clostridium difficile using DNA fingerprints generated with arbitrary polymerase chain reaction primers. FEMS Microbiol. Lett. 71:5-9.

Miller P, Yano J, Yano E, Carroll C, Jayaram K, Ts'o P (1979) Nonionic nucleic acid analogues. Synthesis and characterization of dideoxyribonucleoside methylphosphonates. Biochemistry 18(23):5134-43.

Nielsen P, Egholm M, Berg R, Buchardt O (1991) Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. Science 254(5037): 1497-500.

Nielsen P, Egholm M, Berg R, Buchardt O (1993) Sequence specific inhibition of DNA restriction enzyme cleavage by PNA. Nucleic-Acids-Res. 21(2):197-200.

Nuyten P J M, van Asten F J A M, Gaastra W, van der Zeijst B A M, structural and functional analysis of two Campylobacter jejuni flagellin genes. J. Biol. Chem. 1990, 265,29: 17798-17804.

Olive D. M., M. Johny, and S. K. Sethi, 1990. Use of an alkaline phosphatase-labeled synthetic oligonucleotide probe for detection of Campylobacter jejuni and Campylobacter coli. J. Clin. Microbiol. 28:1565-1569.

Oyofo, B. A., S. A. Thornton, D. H. Burr, T. J. Trust, O. R. Pavlovskis and P. Guerry, 1992. Specific detection of Campylobacter jejuni and Campylobacter coli by using polymerase chain reaction. J. Clin. Microbiol. 30:2613-2619.

Oyofo B. A. and Rottins D. M. 1993. Efficacy of filter types for detecting Campylobacter jejuni and Campylobacter coli in environmental water sample by polymerase chain reaction. Appl. Environ. Microbiol. 59:4090-4095.

Oyofo B. A., Thornton S. A., Burr D. H., Trust T. J., Pavlovskis O. R., and Guerry P. 1992. Specific detection of Campylobacter jejuni and Campylobacter coli by using polymerase chain reaction. J. Clin. Microbiol. 30:2613-2619.

Picken, R. N., Z. Wang, and H. L. Yang, 1987. Molecular cloning of a species-specific DNA probe for Campylobacter jejuni. Mol. Cell Probes. 1:245-259.

Popovic-Uroic, T., C. M. Patton, I. K. Wachsmuth, and P. Roeder, 1991. Evaluation of an oligonucleotide probe for identification of Campylobacter species. Lab. Med. 22:533-539.

Romaniuk, P. J. and T. J. Trust, 1989. Rapid identification of Campylobacter species using oligonucleotide probes to 16S ribosomal RNA. Mol. Cell Probes. 3:133-142.

Römisch K et al. (1989) Nature 340, 478-482.

Roop, R. M., R. M. Smibert, J. L. Johnson, and N. R. Krieg, 1984. Differential characteristics of catalase-positive campylobacters correlated with DNA homology groups. Can. J. Microbiol. 30:938-951.

Sacerdot C. Desen P., Hershey J. Plumbridge J and Grunberg-Manago M (1984). Proc. Natl. Acad. Sci. USA. 81. 7787-7791.

Saiki R, Gelfand D, Stoffel S, Scharf S, Higuchi R, Horn G, Mullis K, Erlich H (1988). Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 239: 487-491.

Sambrook J, Fritsch E F, Maniatis T, 1989. Molecular cloning, a laboratory manual 2nd edition. Cold Spring Harbor Laboratory Press.

Skirrow M. B., Blase M. J., 1992. Clinical and eopidemiological considerations. P. 3-8. In I. Nachamkin, M. J. Blaser, L. S. Tompkins (ed.) Campylobacter jejuni, current status and future trends. American Society for Microbiology, Washington DC.

Stonnet, V. and J. L. Guesdon, 1993. Campylobacter jejuni: specific oligonucleotides and DNA probes for use in polymerase chain reaction-based diagnosis. FEMS Immunol. Med. Microbiol. 7:337-344.

Taylor, D. E. and K. Hiratsuka, 1990. Use of non-radioactive DNA probes for detection of Campylobacter jejuni and Campylobacter coli in stool specimens. Mol. Cell Probes. 4:261-271.

Tenover, F. C., L. Carlson, S. Barbagallo, and I. Nachamkin, 1990. DNA probe culture confirmation assay for identification of thermophilic Campylobacter species. J. Clin. Microbiol. 38:1284-1287.

Thorne, G. M., A. Macone, and D. A. Goldmann, 1990. Enzymatically labelled nucleic acid (NA) probe assays for detection of Campylobacter spp. in human faecal specimens and in culture. Mol. Cell. Probes. 4:133-142.

Tjernberg and Ursing (1989). Clinical strains of Acinetobacter classified by DNA-DNA hybridization. APMIS, 97, 595-605.

Trach K and Hoch J (1989). J. Bact. 171. 1362-1371 (1989).

Van Camp, G., H. Fierens, P. Vandamme, H. Goossens, A. Huygebaert, and R. De Wachter, 1993. Identification of enteropathogenic Campylobacter species by oligonucleotide probes and polymerase chain reaction based on 16S rRNA genes. System Appl. Microbiol. 16:30-36.

Van Belkum A. 1994. DNA fingerprinting of medically important microorganisms by use of PCR. Clin. Microbiol. Rev. 7:174-184.

Walker G, Little M, Nadeau J, Shank D (1992). Isothermal in vitro amplification of DNA by a restriction enzyme/DNA polymerase system. Proc Natl Acad Sci USA 89:392-396.

Wegmüller, B., J. Lüthy, and U. Candrian, 1993. Direct polymerase chain reaction detection of Campylobacter jejuni and Campylobacter coli in raw milk and dairy products. Appl. Environ. Microbiol. 59:2161-2165.

Wegmüller B. Lüthy J. and Candrian U. 1999. Direct polymerase chain reaction detection of Campylobacter coli in raw milk and dairy products. Appl. Environ. Microbiol. 59:2161-2165.

Welsch J., and McClelland M. 1991. Genomic fingerprinting using arbitrarily primed PCR and a matrix of pairwise combinations of primers. Nucleic. Acids. Res. 19:5275-5279.

Wesley, I. V., R. D. Wesley, M. Cardella, F. E. Dewhirst, and B. J. Paster, 1991. Oligodeoxynucleotide probes for Campylobacter fetus and Campylobacter hyointestinalis based on 16S rRNA sequences. J. Clin. Microbiol. 29:1812-1817.

Wu D. Wallace B (1989). The ligation amplification reaction (LAR)—amplification of specific DNA sequences using sequential rounds of template-dependent ligation. Genomics 4:560-569. Barany F (1991). Genetic disease detection and DNA amplification using cloned thermostable ligase. Proc Natl Acad Sci USA 88: 189-193.

Zengel J, Archer R and Lindahl, L (1984). Nucleic Acid Res. 12, 2181-2192.

Zhou, Y. T. and S. Q. Wang. 1989. Application of a biotin-labelled DNA probe to detect Campylobacter. Int. J. Med. Microbiol. 272:186-190.

96 2047 base pairs nucleic acid single linear DNA (genomic) unknown CDS 864..2016 mat_peptide 864..2013 1 GATATCAAGC TTTAGTGACA TGAATTTGAT AAATGGTGCC TAAAGTTCCC ATAATGGCAA 60 TGATAAGCCA AGCTGTAAGA CTTGGCATCA CAAAAGGTGC TAGAATGAAA TCTAAATGTA 120 AAGAATCAAG ATGCTGTGGT TCAAAAAATT CAGCACTGAT CATAGAAATT AAAGGCATTA 180 AGGTTCCTAA AAGGATAAAA GAAAAGGCAA TTTGTTCTGT AGTGTAAGAT TTTCTAAGTT 240 CTCTTACACT TGTAAGAGCT AAGCAGCTAA AAATCCACTC GTGATACCTA TAACTGAATT 300 TTTTAAATCA AAGCCTGAAT GATTTAAATT AATGAGCCCA AGGCTGAGCA ATTAAAAGCA 360 CTCCACCAAA TGCTATTAAA ATTCCTACTC CAGCCTTTGA TGCCAATATT TTCTTTAAAA 420 ACAACAAAAG CTATTAAAGT AATAAAAATA GGAGCAGTTT TTTGAAAAGC AAAAGCTCCG 480 CCTAGTGTAA TATTTGAAAC ATTATAGAAA AACATATATA GTGAAAGCGT GCCTACTACT 540 CCACGAAATA CCAAGAGCCA AAAATGTCCC CCTTCTTTAT GTGCCTTAGA TCGTTTTAAA 600 AGATAGACTA TGAAAAAAAT TCCTATGATA TTTCTAAAAA CATAATTTCT ATAGAACTCA 660 TTTCCTTGCT AAGAATTTTT CCACAAGCNC CCATAAGTGC AAAATCCAAA CATGCTAAAA 720 TCATGAAATA AATTCCTAAA TTATGCTTGA TTACTTTTAG CATTTTTTTT CCTTGACTAA 780 AATCTGTGTT AATTCTAGTC TTTTTTTGCT TAATATTAAG CCAAATTTTA TATAATTTTA 840 AAAATATAAT TTTCTAGGAA AAAAATGCAA AGCATCATAC TTATAGGCAA GCCAAATGTT 900 GGAAAATCAA GTCTTTTTAA TAGAATGGCA AGGCAAAGAA TAGCTATTAC AAGTGATATT 960 TCAGGTACAA CTAGAGATAC AAATAAAACG CAAATTCATA TTCATTCAAA AAAAGCCATG 1020 CTTATTGATA GTGGAGGGCT TGATGAAAGT GATGAACTTT TTAAAAATGT GAAAAAAAAC 1080 ACTTTAAAAG TAGCTAAAGA AAGCGATATC ATACTTTATC TAGTTGATGG GAAATTAGCG 1140 CCTGATGATG AGGATAGACA GTTTTTTTAT TCTTTAAAAA AACTTGGAAA ACCTATAGCC 1200 TTAGTGGTTA ATAAAGTAGA TAATAAAAAA GATGAAGAAA GGGCTTGGGA GTTTGCAAAT 1260 TTTGGAGTAA AGGAAATCTT CAATCTTTCA GTAACCCATA ATGTAGGCTT AGATGAACTT 1320 TATGAATGGC TTGAAAAATT TTTACATGAA GAGTTTTTAA TCCCTGATGA AGAAGAAAAT 1380 TTAGAAGATT TTTTAGAGCA TTATGAAGAA GGAAAAGAAT TTCAATTTAA AGAAGTCGAT 1440 CAAAATCATA TCAGAGTGGG TATTGTAGGG CGTGTAAATG TTGGAAAATC AAGTCTTTTA 1500 AATGCTTTGG TTAAACAAGA ACGCAGTGTT GTAAGTTCTA TCGCAGGAAC TACTATAGAT 1560 CCTGTTAATG AAAGTGTAGT TCATAAAGAT AAAGTGATAG AATTTGTTGA TACTGCAGGT 1620 ATTAGAAAAA GGGGTAAAAT TCAAGGACTC GAACGCTTTG CCCTAAATCG CACGGAAAAA 1680 ATTTTATCTC ATTCTCAAAT AGCACTTTTG GTTTTAGATG CGCATGAGGG CTTTAACGAA 1740 CTTGATGAAC GCATTGCTGG GCTTGTGGCT AAGCATTATT TGGGTGTGAT TATTGTTTTA 1800 AATAAATGGG ATAAAAGTGA GATGGATTTT GATAAAACTG TAAAAGAATT GCATCTTGAT 1860 CGTTTTAAAT TTCTAGCTTA CGCACCTGTG ATTAGCGTAT CGGCTTTAAG TGGAAAAAGG 1920 GTGCATGTTT TACTCGATAA AATTTTGCAA ATTTTTGAGA ATTTCACTCA AAAAATCCAA 1980 ACTTCTAAGC TTATGAAAAT TTCTTTCATA CTTTAAATTT AGGGGTGAAT TACATTTTAC 2040 CAGGAGC 2047 383 amino acids amino acid linear protein unknown 2 Met Gln Ser Ile Ile Leu Ile Gly Lys Pro Asn Val Gly Lys Ser Ser 1 5 10 15 Leu Phe Asn Arg Met Ala Arg Gln Arg Ile Ala Ile Thr Ser Asp Ile 20 25 30 Ser Gly Thr Thr Arg Asp Thr Asn Lys Thr Gln Ile His Ile His Ser 35 40 45 Lys Lys Ala Met Leu Ile Asp Ser Gly Gly Leu Asp Glu Ser Asp Glu 50 55 60 Leu Phe Lys Asn Val Lys Lys Asn Thr Leu Lys Val Ala Lys Glu Ser 65 70 75 80 Asp Ile Ile Leu Tyr Leu Val Asp Gly Lys Leu Ala Pro Asp Asp Glu 85 90 95 Asp Arg Gln Phe Phe Tyr Ser Leu Lys Lys Leu Gly Lys Pro Ile Ala 100 105 110 Leu Val Val Asn Lys Val Asp Asn Lys Lys Asp Glu Glu Arg Ala Trp 115 120 125 Glu Phe Ala Asn Phe Gly Val Lys Glu Ile Phe Asn Leu Ser Val Thr 130 135 140 His Asn Val Gly Leu Asp Glu Leu Tyr Glu Trp Leu Glu Lys Phe Leu 145 150 155 160 His Glu Glu Phe Leu Ile Pro Asp Glu Glu Glu Asn Leu Glu Asp Phe 165 170 175 Leu Glu His Tyr Glu Glu Gly Lys Glu Phe Gln Phe Lys Glu Val Asp 180 185 190 Gln Asn His Ile Arg Val Gly Ile Val Gly Arg Val Asn Val Gly Lys 195 200 205 Ser Ser Leu Leu Asn Ala Leu Val Lys Gln Glu Arg Ser Val Val Ser 210 215 220 Ser Ile Ala Gly Thr Thr Ile Asp Pro Val Asn Glu Ser Val Val His 225 230 235 240 Lys Asp Lys Val Ile Glu Phe Val Asp Thr Ala Gly Ile Arg Lys Arg 245 250 255 Gly Lys Ile Gln Gly Leu Glu Arg Phe Ala Leu Asn Arg Thr Glu Lys 260 265 270 Ile Leu Ser His Ser Gln Ile Ala Leu Leu Val Leu Asp Ala His Glu 275 280 285 Gly Phe Asn Glu Leu Asp Glu Arg Ile Ala Gly Leu Val Ala Lys His 290 295 300 Tyr Leu Gly Val Ile Ile Val Leu Asn Lys Trp Asp Lys Ser Glu Met 305 310 315 320 Asp Phe Asp Lys Thr Val Lys Glu Leu His Leu Asp Arg Phe Lys Phe 325 330 335 Leu Ala Tyr Ala Pro Val Ile Ser Val Ser Ala Leu Ser Gly Lys Arg 340 345 350 Val His Val Leu Leu Asp Lys Ile Leu Gln Ile Phe Glu Asn Phe Thr 355 360 365 Gln Lys Ile Gln Thr Ser Lys Leu Met Lys Ile Ser Phe Ile Leu 370 375 380 86 base pairs nucleic acid single linear DNA (genomic) unknown 3 AGCCTTTTTA ATAGAATGGC AAGACAAAGA ATAGCTATTA CAAGTGATAT TTCAGGCACA 60 ACTAGAGATA CAAATAAAAC GCAAAT 86 117 base pairs nucleic acid single linear DNA (genomic) unknown 4 AGTCTTTTTA ATAGAATGGC AAGACAAAGA ATAGCTATTA CAAGTGATAT TTCAGGTACA 60 ACTAGAGATA CAAATAAAAC GCAAATTCAT ATTCATTCAA AAAAAGCCAT GCTTATT 117 117 base pairs nucleic acid single linear DNA (genomic) unknown 5 AGCCTTTTTA ATAGAATGGC AAGACAAAGA ATAGCTATTA CAAGTGATAT TTCAGGTACA 60 ACTAGAGATA CAAATAAAAC GCAAATTCAT ATTCATTCAA AAAAAGCCAT GCTTATT 117 117 base pairs nucleic acid single linear DNA (genomic) unknown 6 AGTCTTTTTA ATAGAATGGC AAGACAAAGA ATAGCTATTA CAAGTGATAT TTNAGGTACA 60 ACTAGAGATA CAAATAAAAC GCAAATTCAT ATTCATTCAA AAAAAGCCAT GCTTATT 117 117 base pairs nucleic acid single linear DNA (genomic) unknown 7 AGCCTTTTTA ATAGAATGGC AAGACAAAGA ATAGCTATTA CAAGTGATAT TTCAGGCACA 60 ACTAGAGATA CAAATAAAAC GCAAATTCAT ATTCATTCAA AAAAAGCCAT GCTTATT 117 117 base pairs nucleic acid single linear DNA (genomic) unknown 8 AGTCTTTTTA ATAGAATGGC AAGACAAAGA ATAGCTATTA CAAGTGATAT TTCAGGCACA 60 ACTAGAGATA CAAATAAAAC AGAAATTCAT ATTCATTCAA AAAAAGCCAT GCTTATT 117 117 base pairs nucleic acid single linear DNA (genomic) unknown 9 AGCCTTTTTA ATAGAATGGC AAGACAAAGA ATAGCTATTA CAAGTGATAT TTCAGGTACA 60 ACTAGAGATA CAAATAAAAC AGAAATTCAT ATTAATTCAA AAAAAGCCAT GCTTATT 117 86 base pairs nucleic acid single linear DNA (genomic) unknown 10 AGTCTTTTTA ATAGAATGGC AAGACAAAGA ATAGCTATTA CAAGTGATAT TTNAGGTACA 60 ACTAGAGATA CAAATAAAAC AGAAAT 86 86 base pairs nucleic acid single linear DNA (genomic) unknown 11 AGTTTATTTA ACAGAATGGC AAGGCAAAGA ATAGCTATTA CAAGTGAAAT TNNAGGTACT 60 ACAAGAGATA CNAATAAAAC AGAAGT 86 117 base pairs nucleic acid single linear DNA (genomic) unknown 12 AGTTTATTTA ACAGAATGGC AAGGCAAAGA AGAGCTATTA CAAGTGAAAT TTCAGGTACT 60 ACAAGAGATA CCAATAAAAC AGAAGTTTTT ATAAATTCTA AAAAAGCCCT ATTGATT 117 117 base pairs nucleic acid single linear DNA (genomic) unknown 13 AGTTTATTTA ACAGAATGGC AAGGCAAAGA ATAGCTATTA CAAGTGAAAT TTCAGGTACT 60 ACAAGAGATA CCAATAAAAC AGAAGTTTTT ATAAATTCTA AAAAAGCCCT ATTGATT 117 117 base pairs nucleic acid single linear DNA (genomic) unknown 14 AGTTTATTTA ACAGAATGGC AAGGCAAAGA ATAGCTATTA CAAGTGAAAT TTCAGGTACT 60 ACAAGAGATA CCAATAAAAC AGAAGTTTTT ATAAATTCGA AAAAAGCCCT ATTGATC 117 117 base pairs nucleic acid single linear DNA (genomic) unknown 15 AGTTTATTTA ACAGAACGGC AAGGCAAAGA ATAGCTATTA CAAGTGAAAT TTCAGGTACT 60 ACAAGAGATA CCAATAAAAC AGAAGTTTTT ATAAATTCTA AAAAAGCCCT ATTGATT 117 86 base pairs nucleic acid single linear DNA (genomic) unknown 16 AGTTNNTTTA ACAGAATGGC AAGGCAAAGA ATAGCTATTA CAAGTGAAAT TNNAGGTACT 60 ACAAGAGATA CNAATAAAAC AGAAGT 86 87 base pairs nucleic acid single linear DNA (genomic) unknown 17 AGTCTTTTTA ATAGACTTGC AAGAAAGCGC ATAGCTATNA CNAGTGACAT NNGTGGAACN 60 ACAAGAGATA CNAATAAAAT AGAAGTT 87 87 base pairs nucleic acid single linear DNA (genomic) unknown 18 AGTCTTTTTA ATAGACTTGC AAGAAAGCGC ATAGCTATNA CNAGTGACAT AAGTGGAACN 60 ACAAGAGATA CNAATAAAAT AGAAGTA 87 117 base pairs nucleic acid single linear DNA (genomic) unknown 19 AGTCTTTTTA ATAGACTTGC AAGAAAGCGC ATAGCTATCA CCAGTGACAT AAGTGGAACC 60 ACAAGAGATA CCAATAAAAT AGAAGTACAA ATTGATGGCA AAAAAGCCTT GCTTATA 117 117 base pairs nucleic acid single linear DNA (genomic) unknown 20 AGTCTTTTTA ATAGACTTGC AAGAAAGCGC ATAGCTATCA CCAGTGACAT AAGTGGAACC 60 ACAAGAGATA CCAATAAAAT AGAAGTACAA ATTSATGGCA AAAAAGCCTT GCTTATA 117 86 base pairs nucleic acid single linear DNA (genomic) unknown 21 AGTCTTTTTA ATAGACTTGC AAGAAAGCGC ATAGCTATNA CNAGTGACAT AAGTGGAACN 60 ACAAGAGATA CNAATAAAAT AGAAGT 86 117 base pairs nucleic acid single linear DNA (genomic) unknown 22 AGCCTTTTTA ATCGCATAGC AAGGCAAAGA ATCGCCATCA CAAGTGAAAT TTCAGGCACG 60 ACTAGAGATA CAAATAAAAT AAAAGTTAAT ATCAATGGTA AAGAAGCCTT GCTTATC 117 117 base pairs nucleic acid single linear DNA (genomic) unknown 23 AGCCTTTTTA AACGCATAGC AAGGCAAAGA ATCGCCATCA CAAGTGAAAT TTCAGGCACG 60 ACTAGAGATA CAAATAAAAT AAAAGTTAAT ATCAATGGTA AAGAAGCCTT GCTTATT 117 18 base pairs nucleic acid single linear DNA (genomic) unknown 24 CCAAATGTTG GAAAATCA 18 18 base pairs nucleic acid single linear DNA (genomic) unknown modified_base 13 /mod_base= i 25 GCCAAATGTT GGNAARTC 18 18 base pairs nucleic acid single linear DNA (genomic) unknown modified_base /mod_base= i modified_base 15 /mod_base= i 26 AANCCAAATG TTGGNAAR 18 17 base pairs nucleic acid single linear DNA (genomic) unknown modified_base /mod_base= i modified_base 15 /mod_base= i 27 GGCAANCCAA ATGTNGG 17 18 base pairs nucleic acid single linear DNA (genomic) unknown 28 ATGTTGGAAA ATCAAGYC 18 16 base pairs nucleic acid single linear DNA (genomic) unknown 29 ATCAAGTTTA TTTAAC 16 19 base pairs nucleic acid single linear DNA (genomic) unknown 30 TAGACTTCGA AGAAAGCGC 19 22 base pairs nucleic acid single linear DNA (genomic) unknown 31 CATAGCAAGG CAAAGAATCG CC 22 18 base pairs nucleic acid single linear DNA (genomic) unknown 32 GATAGTGGAG GGCTTGAT 18 18 base pairs nucleic acid single linear DNA (genomic) unknown modified_base /mod_base= i 33 GAYAGNGGAG GGCTTGAT 18 18 base pairs nucleic acid single linear DNA (genomic) unknown modified_base /mod_base= i modified_base 12 /mod_base= i modified_base 15 /mod_base= i 34 GAYAGNSSAG GNCTNGAT 18 18 base pairs nucleic acid single linear DNA (genomic) unknown 35 GGGCTTGATG AAAGTGAT 18 24 base pairs nucleic acid single linear DNA (genomic) unknown 36 GGCTTTTTTT GAATGAATAT GAAT 24 20 base pairs nucleic acid single linear DNA (genomic) unknown 37 CCCTCCACTA TCAATAATAG 20 20 base pairs nucleic acid single linear DNA (genomic) unknown 38 GCCATCAATT TGTACTTCTA 20 17 base pairs nucleic acid single linear DNA (genomic) unknown 39 TTAAAAGCTC AGGCTTC 17 19 base pairs nucleic acid single linear DNA (genomic) unknown 40 ACWAGAGATA CMAATAAAA 19 20 base pairs nucleic acid single linear DNA (genomic) unknown 41 CAGGTACAAC TAGAGATACA 20 20 base pairs nucleic acid single linear DNA (genomic) unknown 42 TTAATAGAAT GGCAAGACAA 20 20 base pairs nucleic acid single linear DNA (genomic) unknown 43 TAGAATGGCA AGACAAAGAA 20 20 base pairs nucleic acid single linear DNA (genomic) unknown 44 ATATTTCAGG YACAACTAGA 20 20 base pairs nucleic acid single linear DNA (genomic) unknown 45 ATTCAAAAAA AGCCATGCTT 20 20 base pairs nucleic acid single linear DNA (genomic) unknown 46 TCAAGTTTAT TTAACAGAAT 20 20 base pairs nucleic acid single linear DNA (genomic) unknown 47 AAATTTCAGG TACTACAAGA 20 20 base pairs nucleic acid single linear DNA (genomic) unknown 48 TAAAACAGAA GTTTTTATAA 20 20 base pairs nucleic acid single linear DNA (genomic) unknown 49 CTTTTTAATA GACTTGCAAG 20 20 base pairs nucleic acid single linear DNA (genomic) unknown 50 GACTTGCAAG AAAGCGCATA 20 20 base pairs nucleic acid single linear DNA (genomic) unknown 51 ACATAAGTGG AACCACAAGA 20 20 base pairs nucleic acid single linear DNA (genomic) unknown 52 TCACCAGTGA CATAAGTGGA 20 20 base pairs nucleic acid single linear DNA (genomic) unknown 53 TGGAACCACA AGAGATACCA 20 20 base pairs nucleic acid single linear DNA (genomic) unknown 54 TGATGGCAAA AAAGCCTTGC 20 20 base pairs nucleic acid single linear DNA (genomic) unknown 55 GCATAGCTAT CACCAGTGAC 20 20 base pairs nucleic acid single linear DNA (genomic) unknown 56 CAATAAAATA GAAGTACAAA 20 20 base pairs nucleic acid single linear DNA (genomic) unknown 57 CGCATAGCAA GGCAAAGAAT 20 20 base pairs nucleic acid single linear DNA (genomic) unknown 58 TTTCAGGCAC GACTAGAGAT 20 20 base pairs nucleic acid single linear DNA (genomic) unknown 59 CAATGGTAAA GAAGCCTTGC 20 20 base pairs nucleic acid single linear DNA (genomic) unknown 60 AAGAATCGCC ATCACAAGTG 20 21 base pairs nucleic acid single linear DNA (genomic) unknown 61 TTTTTAATAG AATGGCAAGA C 21 26 base pairs nucleic acid single linear DNA (genomic) unknown 62 CTTTTTAATA GAATGGCAAG ACAAAG 26 21 base pairs nucleic acid single linear DNA (genomic) unknown 63 CATTCAAAAA AAGCCATGCT T 21 29 base pairs nucleic acid single linear DNA (genomic) unknown 64 TTCATATTCA TTCAAAAAAA GCCATGCTT 29 23 base pairs nucleic acid single linear DNA (genomic) unknown 65 ATCAAGTTTA TTTAACAGAA TGG 23 27 base pairs nucleic acid single linear DNA (genomic) unknown 66 ATCAAGTTTA TTTAACAGAA TGGCAAG 27 23 base pairs nucleic acid single linear DNA (genomic) unknown 67 CAATAAAACA GAAGTTTTTA TAA 23 28 base pairs nucleic acid single linear DNA (genomic) unknown 68 CCAATAAAAC AGAAGTTTTT ATAAATTC 28 19 base pairs nucleic acid single linear DNA (genomic) unknown 69 TAATCGCATA GCAAGGCAA 19 21 base pairs nucleic acid single linear DNA (genomic) unknown 70 TATCAATGGT AAAGAAGCCT T 21 20 base pairs nucleic acid single linear DNA (genomic) unknown 71 TTTTAATGCG TTAACAAAAC 20 20 base pairs nucleic acid single linear DNA (genomic) unknown 72 CTAGCAATGC AGAATCTGCA 20 20 base pairs nucleic acid single linear DNA (genomic) unknown 73 CTATCCATTT TGCACTATAG 20 20 base pairs nucleic acid single linear DNA (genomic) unknown 74 ATAGTTCCGG TTCCAGATAT 20 20 base pairs nucleic acid single linear DNA (genomic) unknown 75 TCCAGATATA CGCTTAAATG 20 20 base pairs nucleic acid single linear DNA (genomic) unknown 76 TTTTAATGCT CTAACAAAAC 20 20 base pairs nucleic acid single linear DNA (genomic) unknown 77 CTAGTAACGC AGAGGCNGCA 20 20 base pairs nucleic acid single linear DNA (genomic) unknown 78 CTATCNGTTT TGTACTATNG 20 20 base pairs nucleic acid single linear DNA (genomic) unknown 79 TNNTGATGCG CGTTTGAATG 20 21 base pairs nucleic acid single linear DNA (genomic) unknown 80 AATAAAGTAG ATAATAAAAA A 21 21 base pairs nucleic acid single linear DNA (genomic) unknown modified_base /mod_base= i modified_base 12 /mod_base= i 81 AAYAARGTNG RNAAYAAAAA A 21 117 base pairs nucleic acid single linear DNA (genomic) unknown 82 AGTCTTTTAA ATGCTTTGGT TAAACAAGAA CGCAGTGTTG TAAGTTCTAT CGCAGGAACT 60 ACTATAGATC CTGTTAATGA AAGTGTAGTT CATAAAGATA AAGTGATAGA ATTTGTT 117 169 base pairs nucleic acid single linear DNA (genomic) unknown CDS 2..168 mat_peptide 2..168 83 AACGACTTTT AATGCGTTAA CAAAAGCTAG CAATGCAGAA TCTGCAAACT ATCCATTTTG 60 CACTATAGAG CCAAATAAAG CCATAGTTCC GGNTCCAGAT ATACGCTTAA ATGAGCTWRC 120 AAAAATAGTA AATCCAAATA AAATCCAACA TTCGACTATC GAATTTGTA 169 56 amino acids amino acid linear protein unknown 84 Thr Thr Phe Asn Ala Leu Thr Lys Ala Ser Asn Ala Glu Ser Ala Asn 1 5 10 15 Tyr Pro Phe Cys Thr Ile Glu Pro Asn Lys Ala Ile Val Pro Xaa Pro 20 25 30 Asp Ile Arg Leu Asn Glu Xaa Xaa Lys Ile Val Asn Pro Asn Lys Ile 35 40 45 Gln His Ser Thr Ile Glu Phe Val 50 55 169 base pairs nucleic acid single linear DNA (genomic) unknown CDS 2..169 mat_peptide 2..169 85 AACCACATTT AACGCGCTAA CGAAGGCGCA AAACGCCGAG AGCGCGAACT ATCCGTTYTG 60 CACGATCGAG CCRAATAAAG CCGTCGTGCC GGTGCCCGAT AAGCKCCTAG GCNTGCTARC 120 CAAAATCGTA AATCCAAATA AAATCCAATA CTCCACTATC GAATTCGTC 169 56 amino acids amino acid linear protein unknown 86 Thr Thr Phe Asn Ala Leu Thr Lys Ala Gln Asn Ala Glu Ser Ala Asn 1 5 10 15 Tyr Pro Xaa Cys Thr Ile Glu Xaa Asn Lys Ala Val Val Pro Val Pro 20 25 30 Asp Lys Xaa Leu Gly Xaa Leu Xaa Lys Ile Val Asn Pro Asn Lys Ile 35 40 45 Gln Tyr Ser Thr Ile Glu Phe Val 50 55 125 base pairs nucleic acid single linear DNA (genomic) unknown CDS 2..125 mat_peptide 2..125 87 AACGACTTTT AATGCTCTAA CAAAAGCTAG TAACGCAGAG GCNGCAAACT ATCNGTTTTG 60 TACTATNGAG CCAAATAAAG CTATAGTTNN TGTTNNTGAT GCGCGTTTGA ATGAGCTTTC 120 AAAAA 125 41 amino acids amino acid linear protein unknown 88 Thr Thr Phe Asn Ala Leu Thr Lys Ala Ser Asn Ala Glu Xaa Ala Asn 1 5 10 15 Tyr Xaa Phe Cys Thr Xaa Glu Pro Asn Lys Ala Ile Val Xaa Val Xaa 20 25 30 Asp Ala Arg Leu Asn Glu Leu Ser Lys 35 40 165 base pairs nucleic acid single linear DNA (genomic) unknown CDS 2..165 mat_peptide 2..165 89 TACCCTTTTC AATGCATTAA CGAAAGCAGC GATTGCAGCG GAAAACTTCC CTTTCTGTAC 60 CATTGAACCA AACACAGGTA TTGTTCCTGT ACCAGATCCA CGTTTAGACA AACTTGCTGC 120 GATTGTTAAA CCACAGCGTA TTTTGCCAAC CACAATGGAA TTTGT 165 54 amino acids amino acid linear protein unknown 90 Thr Leu Phe Asn Ala Leu Thr Lys Ala Ala Ile Ala Ala Glu Asn Phe 1 5 10 15 Pro Phe Cys Thr Ile Glu Pro Asn Thr Gly Ile Val Pro Val Pro Asp 20 25 30 Pro Arg Leu Asp Lys Leu Ala Ala Ile Val Lys Pro Gln Arg Ile Leu 35 40 45 Pro Thr Thr Met Glu Phe 50 165 base pairs nucleic acid single linear DNA (genomic) unknown CDS 2..165 mat_peptide 2..165 91 TACCCTTTTC AATGCATTAA CGAAAGCAGC GATTGCAGCG GAAAACTTCC CTTTCTGTAC 60 CATTGAACCA AACACAGGTA TTGTTCCTGT ACCAGATCCA CGTTTAGACA AACTTGCTGC 120 GATTGTTAAA CCACAGCGTA TTTTGCCAAC WACAATGGAA TTTGT 165 54 amino acids amino acid linear protein unknown 92 Thr Leu Phe Asn Ala Leu Thr Lys Ala Ala Ile Ala Ala Glu Asn Phe 1 5 10 15 Pro Phe Cys Thr Ile Glu Pro Asn Thr Gly Ile Val Pro Val Pro Asp 20 25 30 Pro Arg Leu Asp Lys Leu Ala Ala Ile Val Lys Pro Gln Arg Ile Leu 35 40 45 Pro Xaa Thr Met Glu Phe 50 166 base pairs nucleic acid single linear DNA (genomic) unknown CDS 2..166 mat_peptide 2..166 93 TACCCTTTTC AATGCATTAA CGAAAGCAGC GATTGCAGCG GAAAACTTCC CTTTCTGTAC 60 CATTGAACCA AACACAGGTA TTGTTCCTGT ACCAGATCCA CGTTTAGACA AACTTGCTGC 120 GATTGTTAAA CCACAGCGTA TTTTGCCAAC ATACAATGGA ATTTGT 166 55 amino acids amino acid linear protein unknown 94 Thr Leu Phe Asn Ala Leu Thr Lys Ala Ala Ile Ala Ala Glu Asn Phe 1 5 10 15 Pro Phe Cys Thr Ile Glu Pro Asn Thr Gly Ile Val Pro Val Pro Asp 20 25 30 Pro Arg Leu Asp Lys Leu Ala Ala Ile Val Lys Pro Gln Arg Ile Leu 35 40 45 Pro Thr Tyr Asn Gly Ile Cys 50 55 165 base pairs nucleic acid single linear DNA (genomic) unknown CDS 2..165 mat_peptide 2..165 95 TACACTTTTC AATGCCTTAA CCAAAGCTGC TATTGCTGCA GAAAACTTCC CTTTCTGTAC 60 GATCGAACCA AACACCGGGA TTGTACCTGT TCCTGATCCA CGTTTAGACA AATTGACCGC 120 AATTGTTAAA CCGCAACGTG TTATTCCGAC TTCTATGGAA TTTGT 165 54 amino acids amino acid linear protein unknown 96 Thr Leu Phe Asn Ala Leu Thr Lys Ala Ala Ile Ala Ala Glu Asn Phe 1 5 10 15 Pro Phe Cys Thr Ile Glu Pro Asn Thr Gly Ile Val Pro Val Pro Asp 20 25 30 Pro Arg Leu Asp Lys Leu Thr Ala Ile Val Lys Pro Gln Arg Val Ile 35 40 45 Pro Thr Ser Met Glu Phe 50 

What is claimed is:
 1. A polynucleic acid comprising at least one of the following sequences: (i) the polynucleic acid sequence extending from nucleotide position 865 to position 2016 of SEQ ID NO 1, or (ii) one of the polynucleic acid sequences represented by SEQ ID NO 12, 19, or 22, or (iii) a polynucleic acid sequence showing at least 95% identity to any of the sequences as specified in (i) or (ii), or (iv) a polynucleic acid sequence consisting of a fragment containing at least 8 contiguous nucleotides of any of the sequences as specified in (i) to (iii), or (v) a polynucleic acid sequence complementary to any of the sequences as specified in (i) to (iv), or (vi) a polynucleic acid sequence as specified in any of (i) to (v) wherein T is replaced by U.
 2. An oligonucleotide primer comprising from 10 to 30 contiguous nucleotides of a polynucleic acid according to claim 1; wherein said primer can function to allow amplification of part of said polynucleic acid.
 3. An oligonucleotide probe comprising from 10 to 30 contiguous nucleotides of a polynucleic acid according to claim 1; wherein said oligonucleotide probe hybridizes to said polynucleic acid in a hybridization medium comprising 5×SSC at a hybridization temperature between 40° C. and 50° C.
 4. A polynucleic acid comprising at least one of the following sequences: (i) the polynucleic acid sequence extending from nucleotide position 865 to position 2016 of SEQ ID NO 1, or (ii) one of the polynucleic acid sequences represented by SEQ ID NO 1, 12, 19, 22, 25-27, 33, 34, and 81, (iii) a polynucleic acid sequence showing at least 95% identity to any of the sequences as specified in (i) or (ii), or (iv) polynucleic acid sequence complementary to any of the sequences as specified in (i) to (iii), or (v) a polynucleic acid sequence as specified in any of (i) to (iv) wherein T is replaced by U.
 5. An oligonucleotide primer according to claim 2 comprising an oligonucleotide sequences represented by any of SEQ ID NOS 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 80 or 81 or functionally equivalent variants of these primers; wherein each variant shares at least 95% sequence identity with at least one of said SEQ ID NOs and said variant can function to amplify part of a polynucleic acid, as described in claim
 1. 6. A set of primers comprising at least one of the following sets of primers: A: SEQ ID NO 24 and SEQ ID NO 32 B: SEQ ID NO 25 and (SEQ ID NO 33 and SEQ ID NO 34) C: SEQ ID NO 26 and (SEQ ID NO 33 and SEQ ID NO 34) D: SEQ ID NO 27 and (SEQ ID NO 33 and SEQ ID NO 34) E: SEQ ID NO 25 and SEQ ID NO 35 F: SEQ ID NO 26 and SEQ ID NO 35 or variants of these respective primers; wherein each variant shares at least 95% sequence identity with the respective SEQ ID NO, and wherein each set of primers can function to allow amplification of a polynucleic acid according to claim
 1. 7. An oligonucleotide probe obtainable by a process comprising the steps of: a) amplifying, using a pair of primers according to any of claims 5, 6 or 2, a GTP-sites enclosed region present in the GTPase gene of the organism to be determined, and repeating the same for a number of other organisms, phylogenetically closely related to the organism to be determined (=closest neighbors), or suspected of being present in the same type of sample as the organism to be determined. b) determining the sequences of the amplified regions, c) aligning the sequences obtained to allow mutual comparison, and selecting a region in the sequence of the organism to be determined, said region being characterized by a maximal sequence conservation with the organism to be determined, and a maximal sequence divergence (minimum 1 basepair mismatch) towards the other organisms, d) generating a probe comprising a sequence of at least 8 contiguous nucleotides from the region selected in (c), e) defining the hybridization conditions required to obtain the desired hybridization characteristics for the probe selected in (d).
 8. An oligonucleotide probe according to claim 3, hybridizing specifically to the DNA of thermophylic Campylobacter species, and comprising at least one of the sequences represented by SEQ ID NO 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, or 70, or a fragment of at least 8 contiguous nucleotides of any of the sequences represented by SEQ ID NO 1, 12, 19, or 22; wherein said fragment hybridizes specifically to DNA of thermophylic Campylobacter species, or a variant of said probe which has at least 95% sequence identity with said probe, and provided that said variant still hybridizes specifically to the DNA of thermophylic Campylobacter species in a hybridization medium containing 5×SSC at a hybridization temperature between 40° C. and 50° C.
 9. An oligonucleotide probe according to claim 8, hybridizing specifically to the DNA of Campylobacter jejuni, and comprising at least one of the sequences represented by SEQ ID NO 41, 42, 43, 44, 45, 61, 62, 63, 64, or a fragment of at least 8 contiguous nucleotides of the sequence represented by SEQ ID NO 1, wherein said fragment hybridizes specifically to C. jejuni DNA, or a variant of said probe which has at least 95% identity to said probe; wherein said variant still hybridizes specifically to the DNA of C. jejuni, in a hybridization medium containing 5×SSC at a hybridization temperature between 40° C. and 50° C.
 10. An oligonucleotide probe according to claim 8, hybridizing specifically to the DNA of C. coli and comprising at least one of the sequences represented by SEQ ID NO 46, 47, 48, 65, 66, 67, 68, or a fragment of at least 8 contiguous nucleotides of the sequence represented by SEQ ID NO 12; wherein said fragment hybridizes specifically to DNA of C. coli, or a variant of said probe which has at least 95% sequence identity with said probe, and provided that said variant still hybridizes specifically to the DNA of C. coli in a hybridization medium containing 5×SSC at a hybridization temperature between 40° C. and 50° C.
 11. An oligonucleotide probe according to claim 8, hybridizing specifically to the DNA of C. lari and comprising at least one of the sequences represented by SEQ ID NO 49, 50, 51, 52, 53, 54, 55, 56, or a fragment of at least 8 contiguous nucleotides of the sequence represented by SEQ ID NO 19; wherein said fragment hybridizes specifically to DNA of C. lari, or a variant of said probe which has at least 95% sequence identity with said probe, and provided that said variant still hybridizes specifically to the DNA of C. lari in a hybridization medium containing 5×SSC at a hybridization temperature between 40° C. and 50° C.
 12. An oligonucleotide probe according to claim 8, hybridizing specifically to the DNA of C. upsaliensis and comprising at least one of the sequences represented by SEQ ID NO 57, 58, 59, 60, 69, 70, or a fragment of at least 8 contiguous nucleotides of the sequence represented by SEQ ID NO 22; wherein said fragment hybridizes specifically to DNA of C. upsaliensis, or a variant of said probe which has at least 95% sequence identity with said probe, and provided that said variant still hybridizes specifically to the DNA of C. upsaliensis in a hybridization medium containing 5×SSC at a hybridization temperature between 40° C. and 50° C.
 13. A method for the detection and identification of at least one prokaryotic micro-organism, or the simultaneous detection and differentiation of several prokaryotic micro-organisms in a biological sample, said method comprising the steps of: (i) releasing, isolating or concentrating the polynucleic acids present in the sample, (ii) if need be, amplifying the polynucleic acids present in the sample, with a set of primers according to any of claims 5, 6, or 2, (iii) hybridizing the polynucleic acids of (i) or (ii) with at least one of the probes according to any of claims 7-9 or 3, (iv) detecting the hybrids formed in step (iii) with each of the probes under appropriate hybridization and wash conditions, (v) identifying the micro-organisms present in the sample from the differential hybridization signals obtained in (iv).
 14. A method according to claim 13, for detection and/or differentiation of thermophylic Campylobacter species with said primer set of step (ii), of claim 13, comprising a set of primers according to claim 6 and with said probes of step (iii), of claim 13, comprising at least one probe according to claim
 8. 15. A method according to claim 13 or 14, wherein said probes are immobolized on a solid support.
 16. A kit for detection and identification of at least one prokaryotic micro-organism, or the simultaneous detection and/or differentiation of several prokaryotic micro-organisms in a sample, comprising the following components: (i) when appropriate, at least one suitable primer or primer set according to any of claims 5, 6, or 2, (ii) at least one of the probes according to claims 7, 8, 9, or 3, (iii) possibly a buffer or components necessary to produce the buffer enabling a hybridization reaction between these probes and the nucleic acids present in the sample, (iv) possibly a solution or components necessary to produce the solution, enabling washing of the hybrids formed, in step (iii), under the appropriate wash conditions, (v) when appropriate, a means of detecting the hybrids resulting from the preceding hybridization.
 17. A kit according to claim 16, for detection and/or differentiation of thermophylic Campylobacter species in a sample, wherein said primer set comprises a set of primers according to claim 6, and wherein said probes comprise at least one probe according to claim
 8. 18. A process for the detection and/or differentiation of thermophylic Campylobacter species, employing a nucleic acid based assay comprising: using a polynucleic acid, according to claim 1, as a target sequence specific for the thermophylic Campylobacter species.
 19. A method for selecting and generating an oligonucleotide probe comprising the steps of: a) amplifying, using a pair of primers according to any of claims 5, 6, or 2, a GTP-sites enclosed region present in the GTPase gene of the organism to be determined, and repeating the same for a number of other organisms, phylogenetically closely related to the organism to be determined (=closest neighbors), or suspected of being present in the same type of sample as the organism to be determined. b) determining the sequences of the amplified regions, c) aligning the sequences obtained to allow mutual comparison, and selecting a region in the sequence of the organism to be determined, said region being characterized by a maximal sequence conservation with the organism to be determined, and a maximal sequence divergence (minimum 1 basepair mismatch) towards the other organisms, d) generating a probe comprising a sequence of at least 8 contiguous nucleotides from the region selected in (c), e) defining the hybridization conditions required to obtain the desired hybridization characteristics for the probe selected in (d). 